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i 
Abstract 
Amphiphilic block copolymers are well known to undergo self-assembly in aqueous solution 
into a variety of core/shell structures making them useful for various health applications. 
These different architectures are largely a result of the hydrophilic volume or weight fraction 
of the block copolymer. In drug delivery, differences in morphology can largely impact 
performance and each provides their individual advantages. Polymer vesicles, commonly 
referred to as polymersomes, have received significant attention due to their resemblance to 
biological membranes and multifunctional capabilities. This thesis describes the use of novel 
polyester block copolymers containing a hydrophilic poly(ethylene oxide) block and a 
hydrophobic poly(hydroxyalkanoate) block bearing alkene functionality. These polyester 
block copolymers can be functionalized using orthogonal chemistry with a number of 
molecules in order to tune their hydrophilic weight fraction and obtain a variety of different 
desirable morphologies. Additionally, this thesis will describe the synthesis of glycopolymer-
coated vesicles using RAFT polymerization for their potential application in targeted drug 
delivery. 
 
Keywords 
Self-assembly, vesicles, drug delivery, morphology, polyesters, RAFT, vesicles, 
glycopolymers. 
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Chapter 1  
1 Nanocarriers for Biomedical Applications 
Nanocarriers have been widely investigated for their use in drug delivery and other 
biomedical applications.1-4 A number of drugs that show high potential to be effective 
therapeutics are hydrophobic and therefore are insoluble in the bloodstream.5 These drugs 
may degrade in the bloodstream before reaching their site of action and can also be toxic 
to healthy tissues.6 Nanocarriers are promising biomaterials that can be used to solubilize 
drugs, protect the drug from undergoing unwanted physiochemical reactions or 
degradation, as well as target the drug to a specific disease site. Various nanocarriers are 
currently in use today as pharmaceuticals including Doxil (liposomes containing 
doxorubicin), SMANCS (polymer-drug conjugate of neocarzinostatin), and Abraxane 
(albumin-bound paclitaxel nanoparticles) which have all been approved by the Food and 
Drug Administration (FDA) for use as cancer therapeutics.7 Several other drug delivery 
systems are currently at various stages in clinical trials. 
1.1 Introduction to Polymers 
Polymers are macromolecular structures comprised of small monomeric units. These high 
molecular weight molecules are ubiquitous in nature and include proteins, DNA, and 
polysaccharides. Polymers can also be made synthetically by a number of different 
processes to obtain materials with a wide range of desirable properties. Some common 
examples of synthetic polymers include Teflon, polyethylene, nylon, polystyrene, and 
poly(vinyl chloride). 
In comparison to small molecules, which possess very well-defined molecular weights 
and physical properties, polymers are generally polydisperse in that they contain polymer 
chains of unequal length. This is due to the polymerization process, in which chain 
growth is controlled by the probability of attachment of a given monomer. As a result, 
polymers have molecular weight distributions and broadly defined physical properties. 
These properties are primarily dictated by the distribution of polymer chains and the 
number of repeat units in the chain, also known as the degree of polymerization (DP). 
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Due to this distribution, the molecular weight of a polymer is described as an average 
molecular weight calculated from the molecular weights of all the chains in the sample. 
The most commonly reported molecular weight averages include: the number average 
molecular weight (Mn) and the weight average molecular weight (Mw). Mn describes the 
statistical average molecular weight of all polymer chains in the sample, and is defined 
by: 
𝑀" = 	Σ&N&M&Σ&N&  
where Mi is the molecular weight of a chain and Ni is the number of chains of that 
molecular weight.  
Conversely, Mw takes into account the molecular weight of a chain in determining 
contributions to the molecular weight average, and is defined by: 
𝑀) = Σ&N&M&*Σ&N&𝑀&  
Using these two molecular weight averages, the distribution of size or molecular weight 
of a given polymer sample can be obtained, known as the dispersity (Đ):  
Đ = 𝑀)𝑀"  
For an ideal polymer, Đ would be equal to one indicating a completely monodisperse 
sample. However, in practice, the Đ is always greater than one due to the distributions of 
molar masses. These molecular weight averages are commonly determined through size 
exclusion chromatography (SEC), which separates polymer molecules based on their 
size. A polymer solution is injected into a solvent stream that passes through a column 
packed with beads containing various pore sizes (Figure 1.1). Smaller molecules are able 
to pass through the pores in the beads while the larger molecules cannot. As a result, the 
larger the molecule is in solution the faster it will pass through the column as its passage 
is not impeded by the pores. In contrast, smaller molecules take the longest to elute as 
they must travel through numerous pores throughout the column. Thus, fractionation 
  
3 
occurs depending on elution volume Ve, the volume of solvent required to pass the 
molecule through the column to the detector. This results in a distribution of the 
proportions of molecules with different sizes in decreasing order of volume in solution. 
To convert this information from a distribution of volumes to a distribution of molar 
masses, a calibration is performed using polymer standards of known molar mass. 
 
Figure 1.1. Schematic depicting the separation of molecules by size using SEC and 
resulting chromatograph. 
Polymers can also be characterized by their state transition temperatures. Unlike small 
molecules that can exist as solid, liquid or gas separated by phase-transitions occurring at 
very well-defined temperatures, polymers can exhibit an amorphous glassy state, a 
crystalline state, rubbery state and melt state. These states are separated by the glass-
transition temperature (Tg) and melting temperature (Tm) (Figure 1.2). Below the Tg, the 
polymer is in the glassy state. The polymer chains are static and the polymer is hard and 
brittle. Above the Tg, the polymer chains exist in both a static and fluid state resulting in a 
soft or rubbery material. Below the Tm, polymer can contain crystalline domains. Above 
dR
I
Elution Volume (mL)
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the Tm, polymer chains are completely mobile and exhibit fluid-like properties. However, 
the melting transition is only seen for crystalline polymers and occurs when the polymer 
chains fall out of their crystal structures and become a disordered liquid. Phase-transition 
temperatures are determined using differential scanning calorimetry (DSC), a 
thermoanalytical technique in which the difference in the amount of heat required to 
increase the temperature of a sample and a reference is measured over multiple heating 
and cooling cycles. When a phase transition occurs, it will require more or less heat to 
maintain the sample temperature providing Tg and Tm.  
 
Figure 1.2. Schematic of the phase transition temperatures of polymers.  
 
1.2 Amphiphilic Block Copolymers 
A homopolymer is a polymer composed of repeating units of a single monomer (Figure 
1.3). Alternatively, a copolymer is composed of two or more monomers. Block 
copolymers are linear copolymers formed by alternating homopolymer blocks that differ 
in composition or structure. In particular, amphiphilic block copolymers consist of at 
least two regions of distinct chemical nature that undergo phase separation as a result of 
chain association in solvents that selectively dissolve one of the blocks.8 Self-assembly of 
amphiphilic molecules in aqueous solution is driven by the unfavourable interaction of 
the hydrophobic segment with water, forcing hydrophobic chains to associate with each 
other to minimize energetically unfavourable hydrophobe-water interactions. 
Amphiphilic block copolymers can self-assemble in solution, thin-film or bulk and 
demonstrate a wide range of useful applications including energy storage, biomedical 
applications, data transfer and storage, catalysis, and separations devices.9 However, 
solution self-assembly has received significant attention for its ability to form nanoscale 
supramolecular core/shell structures. Amphiphilic block copolymers have been shown to 
Tg TmGlassy
State
Rubbery
State
Melt
State
(Brittle) (Tough/Soft) (Liquid)
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assemble into a vast array of interesting morphologies including spherical micelles,10 
worm-like structures11 and polymeric vesicles.12,13 This behavior is analogous to the self 
assembly of surfactants. However, compared to surfactant micelles, block copolymer 
aggregates typically have much slower exchange kinetics of individual chains leading to 
kinetically stagnant systems.14,15 Additionally, the higher molecular weights and chain 
entanglements result in more resistant assemblies preventing the leakage of cargo. 
 
Figure 1.3. Schematic of a homopolymer, random copolymer, block copolymer, and 
amphiphilic block copolymer. 
 
1.2.1 Morphology 
The morphology of polymer aggregates is primarily the result of the inherent molecular 
curvature and is largely predicted by the hydrophilic volume fraction (fv) of the block 
copolymer. Typically, block copolymers with large hydrophilic blocks will assemble into 
spherical micelles. Lower fv values tend to produce vesicles where as fv values in the 
intermediate range produce cylindrical micelles (Figure 1.4). While approximate volume 
Homopolymer
Random Copolymer
Block Copolymer
Amphiphilic Block Copolymer
hydrophilic hydrophobic
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fractions corresponding to the different morphologies are shown in Figure 1.4, the 
specific quantities are largely influenced by the chemical structures of the given 
polymers. 
 
Figure 1.4. Schematic of the relationship between hydrophilic volume fraction (fv) and 
resulting morphology imaged by cryogenic transmission electron microscopy (TEM). 
The figure was reproduced from Reference 16, permission not required.16 
Different morphologies can each provide their own advantages in terms of biological 
applications. In drug delivery, differences in morphology have the ability to largely 
impact performance.17 Polymer vesicles, commonly referred to as polymersomes, have 
received significant attention due to their resemblance to biological membranes. In 
comparison to biological membranes, polymer vesicles possess increased strength and 
decreased permeability.14 Additionally, polymersomes are potentially multifunctional as 
they possess a hydrophilic core with the ability to encapsulate water-soluble molecules, a 
hydrophobic membrane that can encapsulate hydrophobic species, and a surface to which 
various moieties can be conjugated (Figure 1.5). In contrast, micelles possess a 
hydrophobic core surrounded by a hydrophilic corona that minimizes the interaction of 
fv indicates morphology
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the hydrophobic block with the aqueous surroundings. As a result, spherical and 
cylindrical micelles are capable of encapsulating hydrophobic molecules within their 
cores. However, they lack the capability of encapsulating other types of cargo such as 
hydrophilic drugs, proteins, and nucleic acids. Although most block copolymer-based 
systems being studied for drug delivery are spherical in morphology, work done by 
Discher demonstrated that micelles of cylindrical morphology possess favourable 
properties including higher drug loading and longer circulation lifetime in the 
bloodstream.18,19 Cylindrical micelles provide a larger core volume, allowing the 
encapsulation of more drug per carrier as well as the ability to easily flow through pores 
and capillaries due to their flexibility and small diameter.20 However, only a small 
number of biocompatible block copolymers have been shown to reproducibly form 
cylindrical micelles in solution. Due to the various advantages of different morphologies 
in drug delivery, being able to tune the morphology of biocompatible block copolymer 
aggregates is of high interest. 
 
 
Figure 1.5. Cartoon schematic of the structures of various common morphologies seen 
with amphipilic block copolymers. Adapted with permission from Reference 4 © 2009 
John Wiley & Sons.4 
 
Spherical 
Micelles
Cylindrical 
Micelles
Polymersomes
  
8 
1.2.2 Critical Aggregation Concentration (CAC) 
Polymeric aggregates are in thermodynamic equilibrium with their individual unimers in 
aqueous solution. The critical aggregation concentration (CAC) is the lowest 
concentration of copolymer required in order to form an assembly and provides an 
indirect measure of assembly stability. At low concentrations of polymer, there are an 
insufficient concentration of polymer chains to assemble and they are instead dispersed in 
solution. As the concentration of polymer in solution is increased, more chains are able to 
associate at the aqueous-organic solvent interface and eventually form assembled 
structures. The CAC can be measured through the use of a fluorescent hydrophobic 
molecule, commonly pyrene. To do this, the ratio of the fluorescencent excitation 
intensity of pyrene at 338-339 nm to that at 333-334 nm is measured as a function of 
polymer concentration. As concentration increases and aggregates begin to form, pyrene 
preferentially localizes in the hydrophobic core of the aggregates resulting in an increase 
in the excitation intensity ratio due to the less polar environment. The CAC corresponds 
to the onset of the increase in intensity (Figure 1.6).  
 
Figure 1.6. Graph demonstrating fluorescence intensity of pyrene as a function of 
polymer concentration.  
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Aggregate disintegration can occur as a result of significant dilution causing a premature 
release of cargo. This is a common problem experienced when administering drug-loaded 
micelles into the bloodstream and is known as the burst release effect.21,22 Consequently, 
having assemblies with low CACs or stabilized through crosslinking or other types of 
interactions is highly desirable. 
1.2.3 Biocompatibility 
An important consideration in the design of materials for biomedical applications is 
biocompatibility. Among the many different block copolymers designed for drug 
delivery, those with poly(ethylene oxide) (PEO) as the hydrophilic block have been of 
broadest interest. It is well established that the conjugation of PEO to biologically 
relevant molecules typically enhances their water solubility and hydrolytic stability. PEO 
reduces recognition by the reticuloendothelial system (RES) resulting in longer 
circulation time.3 For example, PEO has been shown to extend in vivo circulation 
lifetimes for insulin, allowing a lower dose frequency and higher patient compliance.23,24 
It is also imperative that the hydrophobic block is biocompatible. Some commonly 
studied hydrophobic blocks with known biocompatibility include poly(propylene oxide), 
polyesters, polycarbonates, and poly(L-amino acid)s (PLAAs).25,26 Of these core-forming 
bocks, polyesters and PLAAs are of particular interest due to their potential 
biodegradability. PLAAs are especially advantageous as they possess functional groups 
allowing chemical conjugation or electrostatic interaction between the amino acid chain 
and various biologically active molecules. PLAAs have been widely studied for drug 
delivery and are currently undergoing clinical trials for the delivery of various 
therapeutics. PLAAs that have been explored as the core-forming block of polymeric 
micelles include poly(β-benzyl L-aspartate) (PBLA), poly(γ-benzyl-L-glutamate) 
(PBGL), poly(N-hexyl stearate-L-aspartamide) (PHSA), poly(L-lysine) (PLL), and 
poly(L-aspartic acid) (PASA) (Figure 1.7).27 However, the long-term immunogenicity 
and biodegradability of the polyamide chain must still be established. In contrast, 
polyesters have shown safe application in humans with well established biodegradability. 
However, few examples in the literature exist of polyesters with functional groups on the 
polymer backbone for post-polymerization chemistry.28-36 The most widely investigated 
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polyesters for use in polymeric nanocarriers include polycaprolactone (PCL), poly(lactic 
acid) (PLA) and poly(glycolic acid) (PGA). 
 
Figure 1.7. Common hydrophobic blocks of a) PLAAs and b) polyesters used for 
amphiphilic block copolymers. 
1.2.4 Size and Polydispersity Index (PDI) of Polymer Assemblies 
Size influences both the clearance and the biodistribution of drug delivery systems. In 
order to utilize polymer assemblies for drug delivery applications, an ideal size must be 
achieved in which particles are large enough to avoid being filtered by the kidneys while 
small enough that they do not accumulate in the liver. This size range is hypothesized to 
be somewhere between 70 and 200 nm.37 When aggregates are less than 200 nm in 
diameter, uptake by the RES of the liver and spleen is limited.5 In contrast, small particles 
(<20-30 nm) are eliminated by the kidneys following administration.38 Particle size is 
often measured by light scattering techniques such as dynamic light scattering (DLS) or 
multiangle light scattering (MALS).  
In addition to size, another important consideration is that particles have a low 
polydispersity index (PDI), meaning there is a narrow distribution in sizes among 
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assemblies (Figure 1.8). Having aggregates of uniform size is important in controlling the 
variability in product performance. The PDI of polymeric aggregates is commonly 
measured by light scattering techniques on a scale of 0.05 to 1 where 0.05 is 
monodisperse and 1 is very polydisperse. 
 
Figure 1.8. Schematic representations of two different samples of nanoparticles 
comparing a monodisperse and polydisperse population obtained from light scattering 
measurements. The figure was reprinted with permission from Reference 38. 
1.2.5 Drug-Core Stability 
Another important characteristic in designing effective polymeric nanocarriers for drug 
delivery is the interaction between the drug and the core of the nanoparticle. Favourable 
drug-core interactions can result in higher drug loading and increased drug 
solubilization.39 These interactions can be made more favourable by changing the 
hydrophobic block length or structure. However, due to the various different structures 
and properties of pharmaceuticals, optimizations made for one system cannot be 
universally applied to all.  
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1.3 Carbohydrate-Functionalized Polymersomes for 
Targeted Delivery 
One of the major challenges in optimizing drug delivery vehicles is to selectively target 
the site of interest.40 One way this can be achieved is through the incorporation of 
carbohydrates onto the surface of molecular assemblies as they are involved in many 
cellular recognition events. Biological saccharides such as glycoproteins, glycoplipids 
and proteoglycans are involved in numerous physiological functions including cell 
adhesion, protection against pathogen invasion, immune response, fertilization and blood 
coagulation through sugar-lectin recognition.41,42 However, the majority of saccharide–
protein interactions are generally too weak to be used in biomaterials and devices. These 
interactions can be amplified through multivalency. Multivalent glycopolymers, or 
polymers possessing pendant saccarides on the backbones, have been reported to exhibit 
strong saccharide–protein interactions. Recent advances in controlled polymerization 
techniques have provided the means to easily access well-defined glycopolymers. In 
particular, reversible addition fragmentation chain transfer (RAFT) polymerization has 
been shown to produce glycopolymers with defined end functionalities, controlled 
molecular weights, low Đ and little toxicity.43-47 
 
Figure 1.9. Synthesis and self-assembly of polyphospazenes with different saccharide 
densities. The figure was reprinted with permission from Reference 42.42 
There are various factors that can influence the binding affinity of glycopolymers to 
lectin including structure of the sacharride, density of sacharrides along the glycopolymer 
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chain, and relative spatial orientation of the glycopolymers upon the substrates of which 
they are displayed. In a recent study, Chen and coworkers synthesized an amphiphilic 
glycosylated polyphosphazene using thiol-yne click chemistry to create 
polyphosphazenes with different saccharide densities, P-37% and P-58% (Figure 1.9).42 
These amphiphilic glycopolymers were then self-assembled and found to form spherical 
micelles. The binding affinities of the assemblies toward lectin were studied and it was 
found that the higher ratio of hydrophobic alkyl groups to β-D-glucose residues 
considerably enhanced the hydrophobic interactions with the lectin Concanavalin A 
resulting in higher binding affinity. This study provides evidence that density of 
glycopolymer on the surface of assemblies influences the strength of binding between 
saccharides and protein.  
In addition to targeted drug delivery, glycopolymers can also serve as therapeutics 
themselves due to their abundant involvement in many biological processes. Synthetic 
glycopolymers can function as biological mimics displaying anticoagulant, anti-
inflammatory, anti-viral, and anti-tumor properties.48 
 
1.4 Thesis Objectives 
The main goal of this thesis is to present two alternative strategies for obtaining 
polymeric nanocarriers with the potential to be used in biomedical applications.  
Chapter 2 will describe the use of novel polyester block copolymers containing a 
hydrophilic PEO block and a hydrophobic poly(3-hydroxy-6-heptenoate) (PHEL) block 
bearing alkene functionality. In this chapter, thiol-ene click chemistry is utilized to 
conjugate various hydrophilic or hydrophobic species onto the polymer backbone (Figure 
1.10). Following solution self-assembly, the effect of changing the polymer’s hydrophilic 
weight fraction on morphology will be investigated. Additionally, this chapter explores 
the conjugation of biologically relevant molecules to the polymer backbone including 
drugs and dyes. 
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Figure 1.10. Schematic representation demonstrating the use of thiol-ene click chemistry 
for the attachment of small molecules to the backbone of newly synthesized PEO-b-
PHEL polymers and subsequent self-assembly. 
Chapter 3 will describe the synthesis of glycopolymer-coated vesicles using two 
alternative strategies (Figure 1.11). First, a novel approach is presented for obtaining 
glycopolymer-functionalized vesicles via aqueous RAFT polymerization of a 
carbohydrate-based monomer directly from the surface of preassembled vesicles. The 
second approach involves the synthesis of glycopolymer-coated vesicles through the 
conjugation of presynthesized glycopolymers bearing alkyne functionality to 
preassembled azide-functionalized vesicles using orthogonal chemistry. 
 
Figure 1.11. Schematic representation of the two approaches for preparing 
glycopolymer-coated vesicles explored in this study. 
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Chapter 4 will summarize the relevant conclusions obtained from both experimental 
chapters and will discuss the future goals and directions of each project. 
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Chapter 2  
2 Functional Polyester Diblock Copolymers Possessing 
Encapsulation and Chemical Conjugation Capabilities 
2.1 Introduction 
Molecular self-assembly describes the phenomenon in which molecules spontaneously 
assemble into complex and ordered structures. The building blocks of life, such as DNA, 
proteins, and biological membranes, all involve a hierarchical organization of small units 
into ordered structures formed by non-covalent interactions.1 The self-assembly of 
nanostructures is particularly useful as it allows the aggregation of molecules too small to 
be manipulated independently into ordered entities that have the ability to produce 
functional materials without human intervention.2 Block copolymer self-assembly has 
attracted considerable attention for several decades due to the ability to form ordered 
structures with various morphologies, including spheres, worms, vesicles, and other 
structures.3-7 These aggregates show promise for a number of applications such as 
catalysis, photoelectric materials, biological imaging, drug delivery, and other areas.  
It is well known that morphology can be tuned by varying the block length, thus changing 
the hydrophilic:hydrophobic ratio of the polymer. The weight fraction of the hydrophilic 
block of the copolymer (fm) has been shown to predict the morphology of spherical 
micelles, cylindrical or “worm-like” micelles, and polymersomes.3,6,8 Additionally, it is 
also possible to tune solution properties of block copolymers through post-polymerization 
functionalization. This allows one polymer precursor to be used in obtaining a number of 
different morphologies through orthogonal chemistry as well as the attachment of cargo. 
A number of studies have investigated this approach for the functionalization of 
polyethers.9-13 In particular, Allen and coworkers recently demonstrated the ability to 
functionalize methoxypoly(ethylene glycol)-b-poly(allyl glycidyl ether) with various 
lengths of alkyl chains using thiol-ene click chemistry to achieve spheres, long 
cylindrical micelles, rods, disks and polymersomes.14  
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Block copolymers in which the hydrophobic block is composed of polyesters are also of 
high interest for use in biomedical applications due to their biodegradability and 
biocompatibility. Polyesters such PCL have been widely investigated as potential drug 
delivery candidates.15-20 However, there are very few examples of polyesters with 
functional groups on the polymer backbone for post-polymerization chemistry.21  
Here we report the synthesis of a new small library of amphiliphilic poly(ethylene oxide)-
b-poly(3-hydroxy-6-heptenoate) (PEO-b-PHEL) block copolymers possessing allyl 
groups on the polymer backbone. We demonstrate that using thiol-ene click chemistry, it 
is possible to tune the fm value of the copolymer through post-modification of the allyl 
groups by the addition of octyl, triethylene glycol (TEG) or acetic acid moieties, thus 
changing the self-assembling properties of the parent polymers. This approach is also 
shown to be useful for the attachment of biologically significant molecules such as 
paclitaxel and Rhodamine B. 
 
2.2 Experimental 
General materials and methods 
Poly(ethylene oxide) monomethyl ether (PEO, Mn = 2000) was purchased from Sigma 
Aldrich and was dried by three azeotropic distillations from toluene and stored in a 
nitrogen filled glovebox. β-6-heptenolactone (β-6-HEL) was synthesized by a procedure 
previously reported for similar lactones22 and spectral data agreed with those previously 
reported.23 The aluminum salen catalyst was synthesized according to a previously 
reported procedure.24 3-Tritylsulfanyl-propionic acid was prepared as previously 
described.25 1-Mercapto-3,6,9,12-tetraoxotridecane (TEG-thiol) was synthesized as 
previously reported.26 Rhodamine derivative (3) was synthesized as previously 
reported.27 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC⋅HCl) 
was purchased from Creo Salus (USA). Paclitaxel was purchased from Ontario 
Chemicals Inc. (Guelph, ON, Canada). Dichloromethane was distilled from calcium 
hydride before use. Anhydrous tetrahydrofuran (THF), N,N-dimethylformamide (DMF) 
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and toluene were obtained from a solvent purification system using aluminum oxide 
columns. Deuterated solvents were purchased from Cambridge Isotopes Laboratories 
(Tewskbury, MA, USA). Solvents were purchased from Caledon Laboratory Chemicals 
(Georgetown, ON, Canada). All other chemical reagents were purchased from Sigma 
Aldrich (St. Louis, MO, USA). All solvents and chemicals were used as received unless 
otherwise noted. Dialysis was performed using Spectra/Por 6 regenerated cellulose 
membranes from Spectrum Laboratories (Rancho Dominguez, CA, USA). Nuclear 
Magnetic Resonance (NMR) spectroscopy was conducted on a Varian Inova 600 MHz 
Spectrometer (Varian, Palo Alto, CA, USA). All 1H and 13C NMR chemical shifts are 
reported in ppm and referenced relative to the residual solvent peak (CHCl3: 1H δ = 7.26, 
13C δ = 77). Coupling constants (J) are expressed in Hertz (Hz). Fourier transform 
infrared (FTIR) spectroscopy was conducted using a Perkin Elmer FT-IR Spectrum Two 
Spectrometer (Waltham, MA, USA) in the universal attenuated total reflectance mode 
(UATR), using a diamond crystal as well as the UATR sampling accessory (part number 
L1050231). Differential scanning calorimetry (DSC) and thermogravimetric analysis 
(TGA) was completed on a DSC Q20 from TA Instruments (Waters, New Castle, DE, 
USA) at a heating rate of 10 °C per minute, under a N2 atmosphere, in an aluminum 
Tzerot pan with approximately 5 mg of sample. Reported Tg values were taken as the 
midpoint temperature of the transition. Size exclusion chromatography (SEC) was 
performed using a Visotek GPC Max VE2001 solvent module equipped with a Visotek 
VE3580 RI detector operating at 30 ˚C, an Agilent Polypore guard column (50x7.5mm) 
and two Agilent Polypore (300x7.5mm) columns connected in series. Samples were 
dissolve in THF (glass distilled grade) at a concentration of approximately 5 mg/mL and 
filtered (pore size: 0.22 µm, ProMax™ syringe filter, PTFE) then injected using a 100 uL 
loop. The THF eluent was filtered and eluted at 1 mL/min for a total of 30 minutes. 
Molecular weight calibration was carried out using polystyrene standards. 
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Synthesis of PEO45-b-PHEL23 and general procedure for the synthesis of PEO-b-
PHEL block copolymers.  
In a nitrogen filled glovebox, β-6-HEL (1.80 g, 14.3 mmol, 26 equiv), the aluminum 
salen catalyst [Al] (Scheme 2.1) (295 mg, 0.54 mmol, 1.0 equiv.) and PEO (Mn = 2000 
Da, 1.08 g, 0.54 mmol, 1.0 equiv.) were added to an ampoule with toluene (20 mL). The 
ampoule was sealed, removed from the glovebox and placed in a preheated oil bath at 85 
˚C for 20 hours. After 20 hours, 0.5 mL of a 10% MeOH in CH2Cl2 solution was added to 
quench polymerization. A crude sample was taken for 1H NMR spectroscopic analysis. 
The remainder was added to hexanes. Hexanes was decanted and the remaining oil was 
dried until constant weight. 1H NMR (600 MHz, CDCl3): δ 1.70-1.71 (m, 48H), 2.02-2.11 
(m, 50H), 2.50-2.61 (m, 49H), 3.38 (s, 3H), 3.64 (bs, 180H), 4.21-4.22 (m, 2H), 4.97-
5.03 (m, 46H), 5.21-5.22 (m, 22H), 5.74-5.81 (m, 23H). Mn based on 1H NMR 
spectroscopy = 4910 g mol-1. SEC (THF): Mn = 5140 g mol-1, Mw = 5550 g mol-1, Đ = 
1.08. FTIR: 2891, 1737, 1343, 1103 cm-1. Tm = 35 ˚C. Tg = -54 ˚C. 
PEO45-b-PHEL45 
This polymer was synthesized as described above for PEO45-b-PHEL23 except that the 
following quantities were used:  β-6-HEL (2.00 g, 15.9 mmol, 51 equiv.), [Al] (170 mg, 
0.31 mmol, 1.0 equiv.), PEO (620 mg, 0.31 mmol, 1.0 equiv.), toluene (20 mL). 1H NMR 
(600 MHz, CDCl3): δ 1.69-1.71 (m, 91H), 2.04-2.07 (m, 95H), 2.47-2.62 (m, 91H), 3.38 
(s, 3H), 3.64 (bs, 180H), 4.20-4.22 (m, 2H), 4.96-5.04 (m, 91H), 5.20-5.23 (m, 45H), 
5.72-5.82 (m, 45H). Mn based on 1H NMR spectroscopy = 7680 g mol-1. SEC (THF): Mn 
= 6630 g mol-1, Mw = 7860 g mol-1, Đ = 1.19. FTIR: 2863, 1829, 1736, 1641, 1168, 1103, 
911 cm-1. Tm = 29 ˚C. Tg = -59 ˚C.  
PEO45-b-PHEL79 
This polymer was synthesized as described above for PEO45-b-PHEL23 except that the 
following quantities were used:  β-6-HEL (2.20 g, 17.4 mmol, 92 equiv.), [Al] (106 mg, 
0.19 mmol, 1.0 equiv.), PEO (387 mg, 0.19 mmol, 1.0 equiv.), toluene (15 mL). 1H NMR 
(600 MHz, CDCl3): δ 1.70 (m, 171H), 2.04-2.09 (m, 170H), 2.48-2.61 (m, 173H), 3.38 
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(s, 3H), 3.64 (bs, 180H), 4.21 (m, 2H), 4.97-5.03 (m, 158H), 5.21-5.22 (m, 81H), 5.74-
5.80 (m, 76H). Mn based on 1H NMR spectroscopy = 11970 g mol-1.  SEC (THF): Mn = 
12910 g mol-1, Mw = 13340 g mol-1, Đ = 1.03. FTIR: 2924, 1737, 1642, 1162, 912, 734 
cm-1. Tm = 22 ˚C. Tg = -46 ˚C. 
General procedure for functionalization of PEO45-b-PHEL45 block copolymers using 
UV-initiated thiol-ene chemistry. 
To a 10 mL Schlenk tube equipped with a stir bar, a mixture of polymer, thiol and 2,2-
dimethoxy-2-phenylacetophenone (DMPA) was added in toluene and degassed by 
bubbling through argon for 30 minutes. The reaction mixture was then placed in an ACE 
Glass photochemistry cabinet containing a medium pressure mercury light source (450 W 
bulb, 2.8 mW/cm2 measured for UVA radiation at the sample position) and irradiated for 
3 hours. 
PEO45-b-PHEL45-octyl 
Polymer = PEO45-b-PHEL45 (50.0 mg, 0.006 mmol); thiol = octanethiol (22.0 mg, 0.150 
mmol); initiator = DMPA (1.90 mg, 0.007 mmol); solvent = toluene (1 mL). The polymer 
was purified by precipitation into cold ethanol. 1H NMR (600 MHz, CDCl3): δ 0.88 (t, 
72H, J = 7.0 Hz), 1.28 (m, 192H), 1.38 (m, 96H), 1.56-1.61 (m, 144H), 1.71 (m, 40H), 
2.08 (m, 40H), 2.47-2.58 (m, 184H), 3.38 (s, 3H), 3.65 (bs, 180H), 4.22 (m, 2H), 4.97-
5.04 (m, 40H), 5.20 (m, 44H), 5.75-5.81 (m, 20H). Mn based on 1H NMR spectroscopy = 
11190 g mol-1. SEC (THF): Mn = 8150 g mol-1, Mw = 9740 g mol-1, Đ = 1.19. FTIR: 
2926, 2856, 1740, 1116 cm-1. Tm = 34 ˚C. Tg = -60 ˚C. 
PEO45-b-PHEL45-TEG 
Polymer = PEO45-b-PHEL45 (50.0 mg, 0.006 mmol); thiol = TEGthiol (27.0 mg, 0.150 
mmol); initiator = DMPA (1.90 mg, 0.008 mmol); solvent = toluene (1 mL). The polymer 
was purified by dialysis using 3500 molecular weight cut off (MWCO) regenerated 
cellulose membrane in DMF. 1H NMR (600 MHz, CDCl3): δ 1.35-1.42 (m, 30H), 1.56-
1.60 (m, 60H), 1.70 (m, 58H), 2.07 (m, 58H), 2.51-2.57 (m, 206H), 2.69 (t, 30H, J = 7.0 
Hz), 3.37 (s, 45H), 3.55 (m, 30H), 3.64 (bs, 300H), 4.21 (m, 2H), 4.96-5.03 (m, 58H), 
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5.20 (m, 44H), 5.73-5.80 (m, 29H). Mn based on 1H NMR spectroscopy = 10200 g mol-1. 
SEC (THF): Mn = 7710 g mol-1, Mw = 8840 g mol-1, Đ = 1.15. FTIR: 2865, 1735, 1104 
cm-1. Tm = 29 ˚C. Tg = -44 ˚C. 
PEO45-b-PHEL45-acid 
Polymer = PEO45-b-PHEL45 (500 mg, 0.063 mmol); thiol = thioglycolic acid (936 mg, 
8.82 mmol); initiator = DMPA (113 mg, 0.441 mmol); solvent = toluene (4 mL). The 
polymer was purified by dialysis using 3500 MWCO regenerated cellulose membrane in 
DMF. Yield = 452 mg, 61%. 1H NMR (600 MHz, CDCl3): δ 1.31 (m, 94H), 1.51 (m, 
197H), 2.44-2.54 (m, 188H), 3.13 (m, 88H), 3.27 (s, 4H), 3.54 (bs, 180H), 4.11 (m, 2H), 
5.07 (m, 46H), 11.18 (bs, 41H). Mn based on 1H NMR spectroscopy = 11820 g mol-1. 
FTIR: 3447, 2940, 1726, 1241, 711 cm-1. Tg = -19 ˚C. 
Synthesis of PEO45-b-PHEL-PTX 
In a flame-dried flask equipped with stir bar, PEO45-b-PHEL45-acid (75.0 mg, 0.007 
mmol) was dissolved in dry DMF (5 mL). Paclitaxel (550 mg, 0.070 mmol), EDC⋅HCl 
(147 mg, 0.710 mmol) and 4-dimethylaminopyridine (DMAP) (33 mg, 0.271 mmol) were 
added and the reaction mixture was stirred overnight. The polymer was precipitated into 
cold EtOH and purified by dialysis using 6-8K MWCO regenerated cellulose membrane 
in DMF. 1H NMR (600 MHz, CDCl3): δ 1.10-1.63 (m, 697H), 1.78-2.47 (m, 827H), 3.24 
(m, 85H), 3.64 (bs, 190H), 3.76 (m, 34H), 4.15 (m, 34H), 4.25 (m, 33H), 4.39 (m, 30H), 
4.92 (m, 35H), 5.13 (m, 45H), 5.33 (m, 36H), 5.64 (m, 41H), 5.95 (m, 34H), 6.17 (m, 
40H), 6.28 (s, 29H), 7.27-7.71 (m, 513H), 8.11 (m, 76H). Mn based on 1H NMR 
spectroscopy = 40030 g mol-1. SEC (THF): Mn = 9010 g mol-1, Mw = 16920 g mol-1, Đ = 
1.88. FTIR: 3447, 2940, 1726, 1241, 711 cm-1. Tg = 131 ˚C. 
Synthesis of anhydride 2 
Dicyclohexylcarbodiimide (DCC) (660 mg, 3.2 mmol, 0.6 equiv.) in dry CH2Cl2 (5 mL) 
was added to a solution of 3-tritylsulfanyl-propionic acid (2.0 g, 5.7 mmol, 1.0 equiv) 
dissolved in dry CH2Cl2 (15 mL). The reaction mixture was stirred at room temperature 
for 10 h and filtered to remove dicyclohexylurea byproduct. The resulting solution was 
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then concentrated, washed with ethyl acetate and dried under vacuum to provide 2 as a 
white solid. Yield = 86%. 1H NMR (600 MHz, CDCl3): δ 2.25 (t, 4H, J = 7.3 Hz), 2.50 (t, 
4H, J = 7.3 Hz), 7.21-7.24 (m, 6H), 7.30 (t, 12H, J = 7.6 Hz), 7.50 (d, 12H, J = 7.6 Hz). 
13C NMR (600 MHz, DMSO): δ 166.9, 144.1, 129.2, 127.7, 126.5, 66.7, 34.3, 25.7. 
FTIR: 3069, 2939, 1819, 1701, 746, 700 cm-1. 
Synthesis of rhodamine derivative 4  
A solution of rhodamine derivative 327  (500 mg, 1.03 mmol, 1.0 equiv.) in dry THF (14 
mL) was added dropwise to a solution of the anhydride 2 (350 mg, 0.516 mmol, 0.5 
equiv.) dissolved in dry THF (10 mL). The reaction mixture was stirred overnight at 
room temperature. The solvent was evaporated and the product was purified by column 
chromatography using neutral alumina (EtOAc:Hexanes (1:1)). Yield = 26%. 1H NMR 
(600 MHz, CDCl3, δ): 1.13 (t, 12H,  J = 7.3 Hz), 2.01-2.04 (m, 2H), 2.41 (t, 2H J = 7.6 
Hz), 2.96-2.97 (m, 2H), 3.25-3.31 (m, 10H), 6.20 (dd, 2H,  J = 8.8, 2.4 Hz), 6.35-6.38 
(m, 4H), 6.62 (bs, 1H), 7.06 (d, 1H, J = 6.5 Hz), 7.14-7.16 (m, 3H), 7.22 (t, 6H, J = 7.6 
Hz), 7.37 (t, 6H, J = 7.0 Hz), 7.41-7.45 (m, 2H), 7.85 (d, 1H, J = 6.5 Hz). MS calcd for 
[M]+ C52H54N4O3S, 814.3917; found, 814.3928. 
Synthesis of PEO45-b-PHEL45-RHD 
To a solution of rhodamine derivative 4 (215 mg, 0.264 mmol, 1.0 equiv.) dissolved in 
dry CH2Cl2 (1 mL) was added a solution of TFA:CH2Cl2 (1:1) (1 mL) dropwise at 0 ˚C. 
The reaction mixture was stirred at room temperature for 4 hr and monitored by TLC. 
The solvent was evaporated, and the resulting thiol product was used immediately 
without further purification. To a 10 mL Schlenk tube equipped with a stir bar, a mixture 
of PEO45-b-PHEL45 (50.0 mg, 0.007 mmol, 1.0 equiv.), deprotected 4 (145 mg, 0.253 
mmol, 36 equiv.) and azobisisobutyronitrile (AIBN) (8 mg, 0.050 mmol, 7.1 equiv.) in 
toluene (6 mL) were added and degassed by three cycles of freeze pump thaw. The 
reaction mixture was then stirred at 80 °C for 6 hours. The resulting polymer was purified 
by dialysis using 6-8K MWCO regenerated cellulose membrane in DMF. Yield = 69%. 
1H NMR (600 MHz, CDCl3): δ 1.15 (t, 65H, J = 7.0 Hz), 1.71 (bs, 94H), 2.02-2.07 (m, 
103H), 2.41 (t, 14H, J = 7.3 Hz), 2.50-2.58 (m, 94H), 2.95-2.96 (m, 11H), 3.25-3.32 (m, 
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51H), 3.64 (bs, 180H), 4.22 (bs, 2H), 4.97-5.04 (m, 84H), 5.21-5.23 (m, 45H), 5.74-5.81 
(m, 40H), 6.22 (dd, 9H, J = 8.8, 2.4 Hz), 6.39 (d, 19H, J = 9.4 Hz), 6.62 (bs, 4H), 7.07 (d, 
6H, J = 7.0 Hz), 7.15-7.18 (m, 14H), 7.24 (t, 28H, J = 7.6 Hz), 7.38 (d, 28H, J = 7.3 Hz), 
7.45 (quin, 12H, J = 6.9 Hz), 7.86 (d, 5H, J = 7.0 Hz). Mn based on 1H NMR 
spectroscopy = 10550 g mol-1. SEC (THF): Mn = 6300 g mol-1, Mw = 7260 g mol-1, Đ = 
1.15.  FTIR: 3081, 2930, 2866, 1739, 1515, 913 cm-1. Tg = -33 ˚C. 
General procedure for self-assembly of PEO45-b-PHELn block copolymers using a 
solvent exchange method. 
Copolymer (8 mg) was dissolved in THF (1 mL) and stirred overnight. The resulting 
solution was filtered (pore size: 0.2 µm, DynaGard® syringe filter, PP) before self-
assembly. Polymer self-assembly was achieved by either the addition of polymer 
dissolved in THF (0.1 mL) to Mili Q water (0.9 mL) while stirring rapidly or vice versa. 
Assemblies were stirred for 5 hours then purified by dialysis using 6-8K MWCO 
regenerated cellulose membrane in purified water overnight. The hydrodynamic radius of 
aggregates was measured by dynamic light scattering (Zetasizer Nano Series, Malvern 
Instruments, UK) at room temperature (25 ˚C) in a glass cuvette. Transmission electron 
microscopy (TEM) imaging was performed using a Phillips CM10 microscope operating 
at an acceleration voltage of 80 kV. 
Procedure for self-assembly of PEO45-b-PHEL79 using film hydration method. 
PEO45-b-PHEL79 (50 mg) was dissolved in 2 mL of CH2Cl2 in a 25 mL round bottom 
flask. A nile red solution in CH2Cl2 was then added to obtain 0.1 w/w/% of nile red 
relative to the copolymer. The CH2Cl2 was removed under a stream of nitrogen to 
produce a film of polymer on the flask. Deionized (DI) water (1 mL/10 mg of polymer) 
was added and the solution was stirred for 0.5 h at 55 °C. The solution was then sonicated 
for 0.5 h and finally stirred for 24 h at 55 °C. The resulting vesicles were characterized by 
confocal fluorescence microscopy using Zeiss LSM 510 DUO Vario using a 63x 
objective. 
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2.3 Results and Discussion 
Synthesis and characterization of PEO-PHEL block copolymers 
β-6-Heptenolactone (β-6-HEL) was selected as the monomer for the preparation of 
functionalizable block copolyesters as it has a pendant terminal alkene that should allow 
for reactions with thiols via well-established thiol-ene chemistry. In addition, recent work 
in the Shaver group has demonstrated that β-lactones undergo controlled coordination 
insertion ring opening polymerization using aluminum salen catalysts.22 Previously, β-6-
HEL has been polymerized using zinc and yttrium complexes and the resulting polymers 
were subsequently functionalized to introduce hydroxyl, epoxide, and pinacolborane 
moieties.28,29 To the best of our knowledge, β-6-HEL has not previously been 
incorporated into block copolymers. This monomer was synthesized using a procedure 
previously reported for similar lactones via epoxide carbonylation using a chromium 
porphyrin complex22 and its identity was confirmed by comparison with previously 
reported spectral data for the same compound.30 For the preparation of block copolymers, 
PEO monomethyl ether with a molar mass of 2000 g mol-1 was used as an initiator and 
the polymerization was conducted in toluene at 85 °C for 20 h using an aluminum salen 
catalyst31 (Scheme 2.1). In order to investigate block copolymers with varying block 
ratios, 26, 50, and 90 equivalents of β-6-HEL were used to provide three different PEO-
b-PHEL block copolymers (Table 2.1). Evaluation of the 1H NMR spectra prior to 
purification showed that the conversion of β-6-HEL varied from 86-88%. The polymers 
were subsequently purified by precipitation into hexanes.  
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Scheme 2.1. Synthesis of PEO-b-PHEL block copolymers.  
 
Table 2.1. Composition and properties of the PEO-b-PHEL block copolymers. 
Copolymer Equiv. 
of HEL 
added 
DP of 
HEL 
(NMR) 
Mn      
(g mol-1) 
(NMR) 
Mn        
(g mol-1) 
(SEC) 
Đ 
(SEC) 
Tg 
(°C) 
Tm 
(°C) 
PEO45-b-PHEL23 26 23 4910 5140 1.08 -54 35 
PEO45-b-PHEL45 51 45 7680 6630 1.19 -59 29 
PEO45-b-PHEL79 92 79 11970 12910 1.03 -46 22, 29 
 
The block copolymers were characterized by 1H NMR spectroscopy, FTIR spectroscopy, 
size exclusion chromatography (SEC), thermogravimetric analysis (TGA) and differential 
scanning calorimetry (DSC). The degree of polymerization (DP) of the polyester block 
was determined using 1H NMR spectroscopy by comparing the integration of the peak at 
3.6 ppm corresponding to the hydrogens on the PEO block with that of the multiplet at 
5.0 ppm corresponding to the protons on the terminal alkenes of the β-6-HEL block 
(Figure 2.1d, Figures A1.4-A1.6). The results indicated that DPs of 23, 45, and 79 were 
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obtained for copolymers PEO45-b-PHEL23, PEO45-b-PHEL45, and PEO45-b-PHEL79 
respectively. These DPs were in good agreement with the equivalents of β-6-HEL added.  
From these DPs, the number average molar mass (Mn) was calculated for each polymer 
(Table 2.1). These ranged from 4910 g mol-1 for PEO45-b-PHEL23 to 11970 g mol-1 for 
PEO45-b-PHEL79. The molar masses were also measured by SEC in THF relative to 
polystyrene standards. As illustrated in Table 2.1, the Mns were in good agreement with 
those obtained by NMR spectroscopy and the dispersity (Đ) was less than 1.2 for each 
copolymer (Figures A1.20-A1.22). The SEC traces are included in the Appendix. 
 
Figure 2.1. 1H NMR overlay of a) PEO45-b-PHEL45-octyl, b) PEO45-b-PHEL45-TEG c) 
PEO45-PHEL45-acid d) PEO45-b-PHEL45. 
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PEO-b-PHEL block copolymers were found to be stable up to 400 °C determined by 
TGA. PEO is a highly crystalline polymer with a Tm of ~58 °C32 while PHEL is an 
amorphous polymer with a Tg of ~ -40 °C.29 Upon their incorporation into block 
copolymers, the resulting materials had both amorphous and crystalline domains, 
suggesting that they undergo phase separation at the nanoscale (Figures A1.27-A1.29). 
The Tm of the copolymers decreased from 35 – 22 °C as the PHEL block length 
increased. This suggests that the crystalline domains became smaller as the PEO content 
of the copolymers decreased. All three of the copolymers underwent cold crystallization 
between the Tm and Tg. The Tg ranged from -59 to -46 °C, with no clear trend relating to 
the changing PHEL block length. However, these Tgs were lower than the previously 
reported Tgs for PHEL of similar DP. This suggests that the presence of non-crystalline 
PEO at these temperatures prior to cold crystallization may enhance segmental motion.  
As one of the main goals of this work was to explore the effects of alkene 
functionalization on the self-assembly of the block copolymers, the self-assembly of 
PEO45-b-PHEL23, PEO45-b-PHEL45, and PEO45-b-PHEL79 was first explored. The 
hydrophilic mass fractions (fm) of the copolymers were calculated as molar mass of PEO 
block/molar mass of copolymer as an estimate of the hydrophilic volume fraction (fv) and 
the results are summarized in Table 2.2. Self-assembly was performed by a solvent 
exchange process involving first the dissolution of the copolymer in THF, followed by 
the addition of water and then dialysis to remove the THF. The resulting assemblies were 
characterized by dynamic light scattering (DLS) and TEM. As shown in Figure 2.2a, 
PEO45-b-PHEL23 with an fm of 0.41 assembled into solid particles that appear to be a 
mixture of true micelles and compound micelles. The Z-average diameter measured by 
DLS was 66 nm, which is in reasonable agreement with the TEM images. This result can 
be compared with those obtained for PEO-PCL block copolymers, whose self-assembly 
has been well-studied. The number of carbons (7) in the lactone monomer β-6-HEL is 
similar to that of caprolactone (6). Micelles were also obtained for similar fm values in 
PEO-PCL copolymers.33 Upon decreasing fm to 0.26 in PEO45-b-PHEL45, solid spherical 
objects with a Z-average diameter of 73 nm were observed (Figure 2.2b). This increasing 
tendency towards the formation of larger assemblies is consistent with the increasing 
  
32 
length of the hydrophobic block and the formation of more compound micelles. In 
comparison to PEO-PCL copolymers, typically fv values between 0.20 and 0.42 result in 
vesicular morphology. For fv >0.42, a mixed morphology of both worm micelles and 
spherical micelles is often observed.34 Upon further decreasing fm to 0.17 in PEO45-b-
PHEL79, vesicles were observed in the TEM images (Figure 2.2c) and the Z-average 
diameter of the assemblies measured by DLS increased to 118 nm.  
Table 2.2. Hydrophilic mass fraction of polymers and their self-assembly properties as 
determined by TEM and DLS. 
Copolymer Hydrophilic mass 
fraction (fm) 
Z-average 
diameter (nm) 
PDI Morphology 
PEO45-b-PHEL23 0.41 66 ± 0.5 0.20 ± 0.01 Micelles, 
compound 
micelles 
PEO45-b-PHEL45 0.26 73 ± 1.1 0.34 ± 0.05 Compound 
micelles 
PEO45-b-PHEL79 0.17 118 ± 2.2 0.31 ± 0.01 Vesicles 
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Figure 2.2. a-c) TEM images and d) fluorescence confocal microscopy image of 
assemblies formed from a) PEO45-b-PHEL23, b) PEO45-b-PHEL45, and c) PEO45-b-
PHEL79 by the solvent switching method and d) PEO45-b-PHEL79 by film hydration. 
As vesicles are more difficult to image by TEM than solid particles due to their tendency 
to collapse upon drying, they were also imaged by fluorescence confocal microscopy 
after incorporation of the hydrophobic dye nile red into their membranes. The limitation 
of this technique is its micrometer-scale resolution, which requires the formation of large 
micrometer-sized vesicles. Such vesicles can be obtained by the hydration of polymer 
films.3,8,34,35 Thus, PEO45-b-PHEL79 and 0.1 wt% nile red were dissolved in CH2Cl2 and 
the solution was used to cast a film on a round bottom flask. Water was then added, and 
the suspension was stirred for 24 hours. As shown in Figure 2.2d, fluorescent vesicles 
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were clearly observed budding from the polymer surface, confirming the tendency of this 
polymer to form vesicles.  
Functionalization of PEO-b-PHEL block copolymers to tune their hydrophilic-
hydrophobic ratios and self-assemblies 
With the block copolymers in hand, the functionalization of the pendant alkenes by thiol-
ene chemistry with the aim of tuning their hydrophilic-hydrophobic ratios was 
subsequently explored. PEO45-b-PHEL45 was chosen as the focus of this work as it had 
an intermediate fm among the three polymers and it was proposed that it would therefore 
be possible to modify the polymers to achieve assemblies ranging from small micelles to 
vesicles as well as intermediary structures. First, the modification of the copolymer with 
hydrophobic 1-octanethiol moieties was investigated. PEO45-b-PHEL45 was reacted with 
25 equivalents per polymer chain of 1-octanethiol using DMPA as a photoinitiator in 
combination with UV irradiation in toluene to afford the functionalized copolymer 
PEO45-b-PHEL45-octyl. The resulting polymer was purified by dialysis in DMF. As 
shown in Figure 2.1a, a reduction in the integration of the peak corresponding to the 
alkene protons at 5.0 ppm from 91 to 41 was observed in the 1H NMR spectrum, which is 
consistent with the functionalization of approximately 24 of the 45 alkenes with 1-
octanethiol. In addition, new peaks appeared at 0.88, 1.28, 1.38 and 1.58 ppm that can be 
assigned to protons on the alkyl chain. The Mn of the polymer measured by SEC 
increased from 6630 to 8150 g mol-1, which is consistent with the addition of mass to the 
polymer. However, it did not increase to the same extent as the actual mass added to the 
polymer. This can be attributed to the grafted architecture. Đ remained unchanged. DSC 
analysis showed that the Tg and Tm of the polymers were also relatively unchanged in 
comparison with PEO45-b-PHEL45 at -60 and 34 °C, respectively.  
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Scheme 2.2. Functionalization of PEO45-b-PHEL45 with octyl chains, TEG, and 
carboxylic acids. 
Table 2.3. Structures and properties of functionalized PEO45-b-PHEL45 copolymers. ND 
= none detected. 
Sample Number of 
functionalized 
alkenes 
Mn (g mol-1) 
(NMR) 
Mn (g mol-1) 
(SEC) 
Đ Tg 
(°C) 
Tm 
(°C) 
PEO45-b-
PHEL45-octyl 
24 11190 8150 1.19 -60 34 
PEO45-b-
PHEL45-TEG 
14 10200 7710 1.15 -44 29 
PEO45-b-
PHEL45-acid 
45 11820 - - -19 ND 
PEO45-b-
PHEL45-PTX 
34 PTX, 11 
acid 
40030 9010 1.88 131 ND 
PEO45-b-
PHEL45-RHD 
5 10550 6300 1.15 -33 ND 
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Next, functionalization of PEO45-b-PHEL45 with 25 equivalents per polymer chain of 
hydrophilic 1-mercapto-3,6,9,12-tetraoxotridecane moieties was performed using the 
same conditions described above to afford PEO45-b-PHEL45-TEG. As shown in Figure 
2.1b, a reduction in the integration of the alkene peak at 5.0 ppm from 91 to 62 was 
observed, suggesting that ~14 alkenes were functionalized with the TEG-SH. In addition, 
new peaks appeared at 3.37 and 2.69 ppm corresponding to the terminal methoxy group 
and methylene adjacent to the sulfur of the TEG chain, respectively. The Mn measured by 
SEC was 7710 g mol-1, similar to that of the octyl derivative and Đ was also similar at 
1.15. In comparison to PEO45-b-PHEL45, PEO45-b-PHEL45-TEG has a somewhat elevated 
Tg of -44 °C, suggesting that the TEG grafts reduce segmental motion. However, the Tm 
remained unchanged.  
An additional approach to tune the hydrophilicity and functionality of the block 
copolymers involved the conjugation of thioglycolic acid to the alkene pendant groups 
using the thiol-ene conditions described above. In this case, 140 equivalents per polymer 
chain were coupled to PEO45-b-PHEL45 to afford PEO45-b-PHEL45-acid. When 140 
equivalents were added, complete functionalization of the alkenes was achieved as shown 
in Figure 2.1c by the disappearance of alkene peaks at 5 ppm in the 1H NMR spectrum 
and the appearance of a peak at 3.1 ppm corresponding to the protons α to the carboxylic 
acid. The presence of carboxylic acids on the polymer made it impossible to obtain 
measurements by SEC due to interactions with the columns. DSC analysis showed that 
PEO45-b-PHEL45-acid had a significantly elevated Tg of -19 °C and no Tm. It is possible 
that hydrogen bonding occurs between the carboxylic acids, reducing segmental motion 
of the polyester block and preventing the crystallization of the PEO block.  
As shown in Table 2.4, following the formula of mass of PEO/total mass of the 
copolymer, the attachment of 24 octyl chains in PEO45-b-PHEL45-octyl results in a 
decrease in fm to 0.18 from 0.26 for PEO45-b-PHEL45. For PEO45-b-PHEL45-TEG, fm was 
calculated as (mass of PEO + mass of TEG)/total mass of copolymer, resulting in 0.44.  
On the other hand, fm values were not calculated for the carboxylic acid-functionalized 
copolymer as it was not obvious what mass should be deemed to contribute to 
hydrophilicity and the charge of the ionized acids was anticipated to override any 
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calculated changes in fm. Self-assembly of the resulting functionalized copolymers was 
studied in the same manner described above. Upon the addition of octyl chains in PEO45-
b-PHEL45-octyl, “worm-like” cylindrical micelles as observed by TEM with lengths on 
the order of a few hundred nm (Figure 2.3a). DLS suggested a Z-average diameter of 143 
nm, but the meaning of this number is limited due to the non-spherical nature of the 
assemblies. Alternatively, the attachment of hydrophilic TEG chains in PEO45-b-PHEL45-
TEG led to micellar structures with a Z-average diameter of 59 nm (Figure 2.3b). By 
TEM, these assemblies were noticeably smaller than those observed for PEO45-b-PHEL45 
(Figure 2.2b). This is expected based on the higher fm for this polymer. On the other hand, 
PEO45-b-PHEL45-acid did not yield any detectable assemblies by DLS or TEM, 
suggesting that this polymer is uniformly hydrophilic and dissolves in aqueous solution. 
Thus, these results show that the morphologies of the polymer assemblies can be readily 
tuned through functionalization of the polyester block. 
Table 2.4. Hydrophilic mass fractions of polymers and their self-assembly properties as 
determined by TEM and DLS. 
Copolymer Hydrophilic mass 
fraction (f) 
Z-average 
diameter (nm) 
PDI Morphology 
PEO45-b-PHEL45-
octyl 
0.18 143 ± 4.0 0.29 ± 0.01 Cylindrical 
micelles 
PEO45-b-PHEL45-
TEG 
0.44 59 ± 0.1 0.258 ± 
0.002 
Micelles, 
compound micelles 
PEO45-b-PHEL45-
acid 
NA - - No assembly 
PEO45-b-PHEL45-
PTX 
0.10 - - Macroscopic 
aggregation 
PEO45-b-PHEL45-
RHD 
0.19 102 ± 0.4 0.178 ± 
0.007 
Micelles, 
compound micelles 
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Figure 2.3. TEM images of assemblies formed by the solvent exchange method from: a) 
PEO45-b-PHEL45-octyl; b) PEO45-b-PHEL45-TEG; c) PEO45-b-PHEL45-RHD self-
assembled using the solvent exchange method. 
Functionalization of PEO-b-PHEL block copolymers with drugs and fluorophores 
In addition to altering the hydrophilic-hydrophobic ratios of the polymers, it was also of 
interest to use the pendant alkene groups to impart new functions to the polymers. To 
demonstrate this, a drug molecule paclitaxel (PTX) and a fluorescent rhodamine dye 
(RHD) were conjugated to the copolymers. Block copolymer micelles have been widely 
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investigated as drug delivery vehicles, in particular for anti-cancer treatment due to the 
possibility of passively and/or actively targeting these systems to tumors. However, a 
major challenge with these systems is poor retention of the drug in the delivery vehicle 
after its administration into the bloodstream. Chemical conjugation of the drug to the 
delivery system has been demonstrated to eliminate or reduce the burst release effect and 
to enable slow and prolonged release of drug.36-39 PTX was selected as the drug to 
demonstrate functionalization of PEO-b-PHEL as it is a widely used anti-cancer 
therapeutic and it is challenging to administer in the absence of a delivery system due to 
its high hydrophobicity and consequently poor water solubility. A number of delivery 
systems for PTX have been developed and covalent conjugation has been shown to slow 
and control its release.40,41 In designing a chemical conjugation strategy, a mechanism for 
release of the active drug should be considered. As PTX possesses three hydroxyl groups, 
with one selectively undergoing esterification,42,43 an ester linkage between PTX and 
PEO45-b-PHEL45 was targeted.  
Reaction of PEO45-b-PHEL45-acid with 100 equivalents of PTX per polymer chain in the 
presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC⋅HCl) 
and 4-dimethylaminopyridine (DMAP) afforded PEO45-b-PHEL45-PTX34 (Scheme 2.3). 
The amount of paclitaxel coupled to the polymer backbone was determined using 1H 
NMR spectroscopy by comparing the integration of the peak corresponding to the 
hydrogen on the stereocenter of the PHEL block (labeled 1’ on the chemical structure in 
Figure 2.4) at 5.21 ppm with that of the peak corresponding to the proton on the tertiary 
carbon adjacent to the amide group (labeled b’ on the chemical structure in Figure 2.4) at 
5.95 ppm. This analysis confirmed that 76% of the pendant carboxylic acid groups on 
PEO45-b-PHEL45-acid were esterified with PTX, resulting in ~34 PTX molecules per 
polymer. SEC analysis provided an Mn of 9010 g mol-1 and a Đ of 1.88. While the Mw 
clearly increases, consistent with the increasing size of the copolymer upon conjugation 
of PTX, the significant increase in Đ and underestimation of the molar mass can likely be 
attributed to tailing due to interactions of the residual carboxylic acids with the column. 
DSC analysis showed that the copolymers were amorphous, with no melting transition 
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observed for the PEO block. However, there was a large increase in the Tg to 131 °C due 
to the incorporation of PTX, which possesses a relatively rigid structure.   
 
 
Scheme 2.3. Synthesis of the PTX conjugate PEO45-b-PHEL45-PTX34 starting from 
PEO45-b-PHEL45-acid. The site of conjugation on PTX is circled. 
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Figure 2.4. 1H NMR spectra of a) PEO45-b-PHEL45-PTX34, b) PEO45-b-PHEL45-acid, 
and c) free paclitaxel. The peaks labeled with ‘ indicate peaks corresponding to 
conjugated molecules. 
The self-assembly of PEO45-b-PHEL45-PTX34 was studied by the solvent exchange 
method involving THF and water. Unfortunately, macroscopic precipitation occurred 
under all of the conditions investigated. This can be attributed to the very low fm value of 
0.10 for this polymer as PTX contributes significantly to the hydrophobic fraction.  
The labeling of polymeric assemblies with fluorophores is also of significant interest for 
monitoring their cell uptake, intracellular trafficking, and biodistribution.44-46 The 
covalent conjugation of the fluorophore ensures that the fluorophore does not diffuse out 
of the assembly and partition into hydrophobic environments such as cell membranes. In 
the current work, the dye selected for conjugation to the polymer is a rhodamine B 
derivative because of its relatively high fluorescence quantum yield and ease of 
modification.27,47 To install a thiol onto the rhodamine for thiol-ene reaction with the 
polymer, 3-tritylsulfanylpropionic acid 125 was first condensed using N, N’-
dicyclohexylcarbodiimide (DCC) to form the anhydride 2 (Scheme 2.4).  An amine-
functionalized rhodamine (3), was synthesized as previously reported,48 then reacted with 
anhydride 2 in CH2Cl2 to afford the protected thiol derivative of rhodamine (4). 
PROTON_JT_251_02_01
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
1111111
PROTON_BR-153-01_01
4534
PROTON_BR-150-01_01
18046
24
d
f
c
be
a
1
d’
e’ b’ c’
a’ f’1’
1
O
NH
Ph
O
O
R'Ph
O
HO
AcO
OH
OAcOBzO
O
a
b
c
d
e
f
O O
O
O
45
H
45
SRO
O
A: PEO45-b-PHEL45-PTX34    R=PTX; R’= PHEL 
B: PEO45-b-PHEL45-acid        R=H
C: Paclitaxel                           R’=H
A
B
C
  
42 
Compound 4 was very sensitive to acid and required purification on neutral alumina 
rather than silica gel to avoid the loss of the trityl protecting group. The trityl protecting 
group was then cleaved using trifluoroacetic acid (TFA) to afford the free thiol, which 
was used immediately in the conjugation reaction due to its susceptibility to oxidation 
and other degradation pathways.  
First, conjugation of the dye to PEO45-b-PHEL45 was attempted using the 
photochemically-initiated thiol-ene reaction described above. This approach was 
unsuccessful, likely due to strong absorbance of the light by the rhodamine. However, 
thermal initiation using azobisisobutyronitrile (AIBN) and 38 equivalents of thiol per 
polymer chain in toluene at 80 °C was successful, yielding PEO45-b-PHEL45-RHD with 5 
fluorophores per polymer chain as determined by 1H NMR spectroscopy (Figure A1.11). 
SEC analysis provided an Mn of 6300 g mol-1 and a Đ of 1.15, which are very similar to 
those of PEO45-b-PHEL45. The addition of the small percentage of rhodamine units to the 
PHEL block had a relatively significant effect on the thermal properties of the copolymer. 
DSC analysis showed that PEO45-b-PHEL45-RHD was amorphous, with no melting 
transition observed for the PEO block. There was also an increase in the Tg to -33 °C 
from -59 °C of PEO45-b-PHEL45. Self-assembly of PEO45-b-PHEL45-RHD was 
investigated using the solvent exchange method with THF and water as described above. 
As shown in Figure 2.3c and Table 2.4, this copolymer self-assembled to form solid 
spherical assemblies that were likely compound micelles with a Z-average diameter of 
102 nm. The larger size of these assemblies relative to those formed by PEO45-b-PHEL45 
can likely be attributed to the decreased fm of PEO45-b-PHEL45-RHD. This demonstrates 
that these new copolymers with pendant alkene groups can also be readily used to 
provide fluorescently-labeled polymer assemblies.  
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Scheme 2.4. Synthesis of a thiol-functionalized rhodamine derivative and its conjugation 
to PEO45-b-PHEL45. 
 
2.4 Conclusions 
In this work, a small library of novel PEO-b-PHEL block copolymers possessing pendant 
allyl groups and varying degrees of polymerization for the hydrophobic block were 
synthesized. The parent polymers were studied for the formation of different 
morphologies and were found to produce spherical micelles (PEO45-b-PHEL23 and 
PEO45-b-PHEL45) as well as vesicles (PEO45-b-PHEL79). It was also found that PEO45-b-
PHEL45 could be functionalized with octyl, TEG or acid groups to significantly alter fm, 
in turn influencing their self-assembly behaviour and resulting morphologies. In addition, 
the successful attachment of paclitaxel and rhodamine B using thiol-ene chemistry to the 
PHEL block afforded biologically interesting polymers capable of forming various 
morphologies upon self-assembly in aqueous media. This technique afforded well-
defined polymers with high rates of conversion and low dispersities, making them ideal 
candidates for biological applications. 
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Chapter 3  
3 Glycopolymer-functionalized Vesicles via Azide-Alkyne 
Click Chemistry 
3.1 Introduction 
Amphiphilic block copolymers have been shown to assemble into a vast array of 
interesting morphologies including spherical micelles,1 cylindrical “worm-like” micelles 
and vesicles.2,3 In particular, polymer vesicles, commonly referred to as polymersomes, 
have received significant attention due to their resemblance to biological membranes. In 
comparison to biological membranes, polymer vesicles possess increased strength and 
decreased permeability. Additionally, polymersomes are potentially multifunctional as 
they possess a hydrophilic core with the ability to encapsulate water-soluble molecules, a 
hydrophobic membrane that can encapsulate hydrophobic species, and a surface to which 
various moieties can be conjugated. Based on these properties, there has been specific 
interest in the use of polymersomes in biomedical applications, particularly in drug 
delivery.4,5 However, one of the major challenges in optimizing drug delivery vehicles is 
to selectively target the site of interest.6 One way this can be achieved is through the 
incorporation of carbohydrates onto the surface of molecular assemblies as they are 
involved in many cellular recognition events. Although saccharide–protein interactions 
are generally too weak to be used in biomaterials and devices, the interactions can be 
amplified through multivalency. Multivalent glycopolymers have been reported to exhibit 
strong saccharide–protein interactions.7 
Previous work in our group has involved the functionalization of polymersomes with 
glycodendrimers designed to interact with influenza viruses thereby intercepting the 
infection process.8 This was achieved through the conjugation of N-acetylneuraminic acid 
(Neu5Ac, commonly referred to as sialic acid) to the peripheries of polyester dendrons 
and then their subsequent conjugation to the polymersome surface in order to inhibit the 
binding of viral hemagglutinin to sialic acids on host cells, thus preventing viral uptake. 
Additionally, the water-soluble drug zanamivir was incorporated into the core of the 
polymersome to prevent the release of progeny virus from the host cells, inhibiting viral 
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replication. It was shown that incorporation of carbohydrate-functionalized dendrons onto 
the polymersome surface led to a 2000-fold enhancement in protein binding compared to 
that of a small-molecule analogue.8 However, when tested in vitro, these assemblies were 
shown to be ineffective against the influenza virus. It is presumed that this ineffectiveness 
may be due to the rigidity of the dendrimers on the polymersome periphery making it 
difficult for their functionalities to easily surround the virus. It is hypothesized that using 
a system with more molecular flexibility may improve multivalent binding. This may be 
achieved by using a linear glycopolymer system as opposed to glycodendrimers as they 
possess much more flexibility (Figure 3.1). 
 
Figure 3.1. Schematic representation depicting rigidity of a glycodendrimer-
functionalized polymersome system compared to a glycopolymer-functionalized system. 
Although numerous studies have shown that glycodendrimers exhibit better protein 
interactions compared to their linear counterparts, few studies have explored the 
performance of glycopolymer-functionalized micelles compared to glycodendrimer 
micelles.9,10 In addition to structure, there are several other factors that may influence the 
affinity and specificity of multivalent binding. Some examples include the density of 
glycopolymer chains as well as glycopolymer chain length. However, few reports have 
explored the effect of glycopolymer density11 and glycopolymer chain length12 on protein 
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binding interactions. The goal of this study was to create a small library of glycopolymer-
coated vesicles with varying densities and chain lengths of glycopolymer on the vesicle 
surface (Table 3.1). The saccarhide-protein binding of these glycopolymer-coated 
vesicles can then be determined and compared using a lectin binding assay. 
Table 3.1. Overview of varying density and glycopolymer chain length to afford a small 
library of glycopolymer-coated vesicles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Percentages of functionalized terminal groups 
present on glycopolymer surface 
100% 10% 
 
 
Glycopolymer 
chain length 
 
8 
High density, short 
chain glycopolymer-
coated vesicles 
Low density, short chain 
glycopolymer-coated 
vesicles 
 
20 
High density, medium 
chain glycopolymer-
coated vesicles 
Low density, medium 
chain glycopolymer-
coated vesicles 
 
40 
High density, long chain 
glycopolymer-coated 
vesicles 
Low density, long chain 
glycopolymer-coated 
vesicles 
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Three general approaches can be envisioned for the incorporation of glycopolymers onto 
the surface of vesicles. One approach involves the synthesis of amphiphilic block 
copolymers with a hydrophilic block containing saccharide units, followed by their 
assembly into vesicles. The majority of existing studies utilize this linear approach to 
afford glycopolymer-decorated vesicles.6,13-17 Another possible approach involves the 
assembly of vesicles containing functional groups on the surface followed by their 
reaction with glycopolymers possessing complimentary groups at their terminus using 
orthogonal chemistry.9,11 The third approach involves the assembly of vesicles in which 
saccharide monomer can be polymerized directly from the vesicle surface which, to the 
best of our knowledge, has not yet been explored in the literature. This work will describe 
the efforts towards obtaining glycopolymer-coated vesicles using the latter two methods 
described above (Figure 3.2). 
 
Figure 3.2. Two approaches for preparing glycopolymer-coated vesicles explored in this 
study. 
In the first approach, glycopolymer-functionalized vesicles will be accessed using a novel 
method involving reversible addition-fragmentation chain transfer (RAFT) 
polymerization of carbohydrate-based monomers directly from the surface of 
preassembled vesicles. This can be achieved using a commercially available amphiphilic 
Vesicles with azide
groups on surface
PGaln
Acrylamide-
funcitonalized
β-D-galactose
monomer
Vesicles with CTA
on surface
PBD-b-PEO-CTA
PBD-b-PEO
Glycopolymer-
functionalized 
vesicles
PBD-b-PEO-N3
PBD-b-PEO
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block copolymer poly(butadiene-b-ethylene oxide) (PBD-b-PEO) and functionalizing the 
terminus with a RAFT chain-transfer agent (CTA). Following self-assembly of the 
functionalized block copolymers into vesicles in aqueous solution, it is then possible to 
polymerize a monomer using RAFT polymerization from the vesicle surface. Vesicles 
with varying glycopolymer chain length and chain density can be achieved by varying the 
equivalents of PBD-b-PEO chains functionalized with CTA, the equivalents of monomer, 
and adjusting reaction time. 
In the second approach, glycopolymer-functionalized vesicles will be obtained using 
alkyne-azide click chemistry. This can be achieved through the functionalization of PBD-
b-PEO with an azide moiety. These block copolymers can undergo self-assembly in 
aqueous solution with varying equivalents of PBD-b-PEO and PBD-b-PEO-N3 to provide 
vesicles with varying equivalents of azide on the surface. Additionally, glycopolymers 
can be synthesized via RAFT polymerization from a CTA possessing alkyne 
functionality. Orthogonal chemistry can then be used in aqueous conditions to 
functionalize the azide groups on the vesicle surface with glycopolymer. This study will 
use a β-D-galactose based monomer possessing acrylamide functionality as a simple 
model. The incorporation of nile red into assemblies will allow assays to be performed on 
the resulting glycopolymer-functionalized vesicles to determine and compare their 
protein-binding capabilities. 
 
3.2 Experimental 
General Materials and Methods 
Poly(butadiene-b-ethylene oxide) (PBD-b-PEO) (PDI = 1.15) with a composition of 6000 
g mol-1 PBD (>80% 1,2 addition) and 4000 g mol-1 PEO was purchased from Polymer 
Source (Dorval, QC, Canada) and dried by three azeotropic distillations from toluene 
before use. Alkyne-functionalized CTA (7),18 D-galactose pentaacetate,19 and PBD-b-
PEO-N320 were prepared as previously reported. Anhydrous CH2Cl2 and triethylamine 
(NEt3) were distilled from calcium hydride (CaH2). Anhydrous acetonitrile and methanol 
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(MeOH) were obtained from a solvent purification system using aluminum oxide 
columns. Deuterated solvents were purchased from Cambridge Isotopes Laboratories 
(Tewskbury, MA, USA). Solvents were purchased from Caledon Laboratory Chemicals 
(Georgetown, ON, Canada). All other chemical reagents were purchased from Sigma 
Aldrich (St. Louis, MO, USA). All solvents and chemicals were used as received unless 
otherwise noted. Dialysis was preformed using Spectra/Por 6 regenerated cellulose 
membranes from Spectrum Laboratories (Rancho Dominguez, CA, USA). Nuclear 
Magnetic Resonance (NMR) spectroscopy was conducted on a Varian Inova 600 MHz 
Spectrometer (Varian, Palo Alto, CA, USA). All 1H and 13C NMR chemical shifts are 
reported in ppm and referenced relative to the residual solvent peak (CHCl3: 1H δ = 7.26, 
13C δ = 77.2, (CD3)2SO: 1H δ = 2.50, 13C δ = 39.5, D2O: 1H δ = 4.79, CD3OD: 1H δ = 
3.31). Coupling constants (J) are expressed in Hertz (Hz). Size exclusion chromatography 
(SEC) was performed using a Waters Separations Module 2695 equipped with a 
Refractive Index Detector (Waters 2414) and three PLaquagel-OH 40 8µm (300x7.5mm) 
columns (Polymer Laboratories) connected in series and to a PLaquagel-OH 8µm guard 
column. The calibration was performed using poly(methyl methacrylate) standards. DLS 
was performed on a ZetaSizer Nano instrument from Malvern. Fourier transform infrared 
(FTIR) spectroscopy was conducted using a Perkin Elmer FT-IR Spectrum Two 
Spectrometer (Waltham, MA, USA) in the universal attenuated total reflectance mode 
(UATR), using a diamond crystal as well as the UATR sampling accessory (part number 
L1050231). 
Synthesis of 2-azidoethanol (2) 
A mixture of 2-bromoethanol (50 g, 0.40 mol, 1.0 equiv.) and sodium azide (26 g, 0.40 
mol, 1.0 equiv.) was heated to reflux overnight with stirring. The resulting mixture was 
put under vacuum for 4 hours followed by dilution with 200 mL diethyl ether. The 
solution was filtered through celite and concentrated. Purification was performed by 
distillation at 140 °C (190 mbar) to provide compound 2 as a light yellow liquid. Yield = 
86%. 1H NMR (600 MHz, CDCl3): δ 3.34 (t, 2H, J = 5.28 Hz), 3.56 (s, 1H), 3.69 (t, 2H, J 
= 5.28 Hz). Spectral data agreed with those previously reported.19 
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Synthesis of galactose derivative 3 
Galactose derivative 119 (20.0 g, 51.0 mmol, 1.0 equiv.) was dissolved in 120 mL of 
anhydrous CH2Cl2 and azidoethanol (2) (6.69 g, 76.9 mmol, 1.5 equiv.) was added via 
syringe. The resulting solution was cooled to 0 °C and BF3⋅OEt2 (25.4 g, 179 mmol, 3.5 
equiv.) was added dropwise. The reaction mixture was stirred overnight under argon. 
After dilution with CH2Cl2, the reaction mixture was washed with 1M HCl, saturated 
NaHCO3 and water. The organic phase was dried over MgSO4, filtered and concentrated. 
Purification was performed by flash chromatography on silica gel (ethyl acetate/hexane 
1/1) yielding compound 3 as a yellow syrup. Yield = 69%. 1H NMR: (600 MHz, CDCl3, 
δ): 1.97 (s, 3H), 2.03 (s, 3H), 2.04 (s, 3H), 2.14 (s, 3H), 3.28-3.31 (m, 1H), 3.47-3.51 (m, 
1H), 3.66-3.70 (m, 1H), 3.91-3.93 (m, 1H), 4.02-4.05 (m, 1H), 4.09- 4.13 (m, 1H), 4.10-
4.19 (m, 1H), 4.55-4.56 (d, 1H, J = 8.2 Hz), 5.00-5.03 (dd, 1H, J = 10.6, 3.5 Hz), 5.21-
5.24 (dd, 1H, J = 10.3, 7.9 Hz), 5.38-5.39 (dd, 1H, J = 3.5, 1.2 Hz). Spectral data agreed 
with those previously reported.19 
Synthesis of galactose derivative 4 
Lindlar catalyst (0.5 g) and p-toluenesulfonic acid⋅H2O (0.52 g, 2.7 mmol, 1.1 equiv.) 
were added to a solution of compound 3 (1.0 g, 2.4 mmol, 1.0 equiv.) in methanol (17 
mL) under argon. The reaction mixture was stirred under H2 for 8 hours. The reaction 
mixture was filtered through a plug of celite and concentrated to yield compound 4 as an 
orange viscous liquid. 1H NMR (400 MHz, DMSO-d6): δ 1.91 (s, 3H), 2.01 (s, 3H), 2.03 
(s, 3H), 2.11 (s, 3H), 3.72-3.89 (m, 2H), 4.06 (d, 2H, J = 6.3 Hz), 4.24 (t, 1H, J = 6.4 Hz), 
4.79 (d, 1H, J = 8.2 Hz), 4.98 (dd, 1H, J = 10.4, 8 Hz), 5.17 (dd, 1H, J = 10.2, 3.5 Hz), 
5.28 (d, 1H, J = 3.5 Hz). Spectral data is consistent with published values.19 
Synthesis of protected galactose monomer 5 
A suspension of compound 4 (14 g, 35 mmol, 1.0 equiv.) was dissolved in 215 mL of 
anhydrous CH2Cl2 and cooled to 0 °C while stirring. Acryloyl chloride (6.4 g, 70 mmol, 
2.1 equiv.), diisopropylethylamine (DIPEA) (48 mL, 280 mmol, 8 equiv.) and 4-
dimethylaminopyridine (DMAP) (0.15 g) were added to the reaction mixture. The 
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solution was stirred at room temperature under argon overnight. The reaction mixture 
was washed with saturated NH4Cl, NaHCO3 and water. The organic phase was dried over 
magnesium sulphate, filtered and butylated hydroxytoluene (BHT) was added to the 
solution as an inhibitor before being concentrated. The resulting material was purified by 
flash chromatography on silica (ethyl acetate/hexanes 3/1) to provide compound 5 as a 
yellow syrup. Yield = 40%. 1H NMR (600 MHz, CDCl3): δ 2.00 (s, 3H), 2.05 (s, 3H), 
2.06 (s, 3H), 2.17 (s, 3H), 3.48-3.53 (m, 1H), 3.60-3.65 (m, 1H), 3.73-3.77 (m, 1H), 3.90-
3.94 (m, 2H), 4.11-4.19 (m, 2H), 4.49 (d, 1H, J = 8.2 Hz), 5.03 (dd, 1H, J = 10.6, 3.5 
Hz), 5.19 (dd, 1H, J = 10.6, 8.2 Hz), 5.41 (d, 1H, J = 3.5 Hz), 5.67 (d, 1H, J = 10.0 Hz), 
6.12 (dd, 1H, J = 17.0, 10.0 Hz). Spectral data is consistent with published values.19 
Synthesis of deprotected galactose monomer 6 
To a solution of compound 5 (0.50 g, 1.1 mmol) in anhydrous methanol (10 mL), 25% 
sodium methoxide in methanol (230 uL, 1.1 mmol) was added dropwise. The reaction 
mixture was stirred at room temperature for 1.5 hours. Dowex cation exchange resin (H-
form) was added until a pH of 6 was obtained and then the solution was filtered and 
concentrated using a rotary evaporator. The residue was dissolved in water, filtered and 
freeze-dried to provide 6 as an off white solid. Yield = 76 %. 1H NMR (600 MHz, D2O): 
δ 3.48-3.52 (m, 3H), 3.62 (dd, 1H, J = 9.9, 3.5 Hz) 3.66 (dd, 1H, J = 7.6, 4.1 Hz), 3.72-
3.81 (m, 3H), 3.90 (d, 1H, J = 3.5 Hz), 3.97-4.00 (m, 1H), 4.38 (d, 1H, J = 8.2 Hz), 5.74 
(d, 1H, J = 10.6 Hz), 6.18 (d, 1H, J = 17.6 Hz), 6.26 (dd, 1H, J = 17.3, 10.3 Hz). Spectral 
data is consistent with published values.19 
Preparation of RAFT chain-transfer agent (CTA) functionalized PBD-b-PEO (PBD-
b-PEO-CTA) 
A solution of 2-(butylthiocarbonothioylthio)-2-methylpropanoic acid18 (200 mg, 0.79 
mmol, 1.0 equiv.) in anhydrous CH2Cl2 (4 mL) was added to a flame-dried flask and the 
flask was fitted with a magnetic stir bar and reflux condenser.  Thionyl chloride (230 µL, 
4.0 mmol, 5.0 equiv.) was added dropwise using a needle and syringe. The reaction 
mixture was heated at reflux for 2 hours. CH2Cl2 was removed under vacuum. PBD-b-
PEO (50 mg) was dried through azeotrope formation with toluene (x3) and redissolved in 
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0.5 mL of freshly distilled CH2Cl2 in a separate flame-dried flask. Next, NEt3 (3 mL) was 
added to the dissolved PBD-b-PEO and the mixture was cooled to 0 °C. The acid 
chloride RAFT agent was then dissolved in CH2Cl2 (0.5 mL) and added to the reaction 
mixture dropwise. The reaction was slowly brought to room temperature and stirred 
overnight. The solvent was then removed using a rotary evaporator and replaced with a 
minimal amount of DMF. The resulting solution was then dialyzed using a 6-8 kg mol-1 
MWCO membrane. After 48 hours of dialysis with changing the solvent reservoir every 
12 hours, the DMF was removed in vacuo. Based on 1H NMR spectroscopy, 85% of the 
polymer termini were functionalized. Yield = 79 %. 1H NMR (600 MHz, CDCl3): δ 0.92-
0.95 (m, 3H), 1.05-1.45 (m, 243H), 1.70 (s, 6H), 1.90-2.12 (m, 173H), 3.52-3.77 (m, 
364H), 4.25-4.27 (m, 2H), 4.87-5.4.94 (m, 231H), 5.31-5.57 (m, 138 H). 
Synthesis of CTA functionalized PEO 2K 
To a flame-dried round bottom flask fitted with a magnetic stir bar, methoxy 
poly(ethylene oxide) (PEO) (Mn = 2000 Da, 500 mg, 0.25 mmol, 1.0 equiv.), 2-
(butylthiocarbonothioylthio)-2-methylpropanoic acid18 (340 mg, 1.3 mmol, 5.2 equiv.), 
DMAP (30 mg, 0.25 mmol, 1.0 equiv.), 4-(dimethylamino)pyridinium-4-toluene 
sulfonate (DPTS) (140 mg, 0.48 mmol, 1.9 equiv.) was added to dry CH2Cl2 (10 mL). 
While stirring, N,N’-Dicyclohexylcarbodimide (DCC) (600 mg, 2.9 mmol, 12 equiv.) was 
added and the reaction mixture was stirred for 48 hours at 30 °C. The reaction mixture 
was filtered through celite to remove insoluble byproduct. The resulting product was then 
purified by dialysis against DMF using a 6-8 kg mol-1 MWCO membrane. After 48 hours 
of dialysis with changing the solvent reservoir every 12 hours, the DMF was removed in 
vacuo. Based on 1H NMR spectroscopy, 100% of the polymer termini were 
functionalized. Yield = 60 %. 1H NMR (600 MHz, CDCl3): δ 0.90 (t, 3H, J = 7.3 Hz), 
1.23 (bs, 2H), 1.36-1.43 (m, 3H), 1.60-1.65 (m, 3H), 1.67 (s, 6H), 3.25 (t, 2H, J = 7.6 
Hz), 3.35 (s, 3H), 3.49-3.74 (m, 164H), 4.22-4.24 (m, 2H). 
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Synthesis of PAcGal6 from alkyne-functionalized CTA and general procedure for 
the synthesis of PAcGaln glycopolymers. 
Acetonitrile was subjected to three cycles of freeze pump thaw. Before use, β-D-
galactose pentaacetate monomer 5 was dissolved in CH2Cl2 and added to the top of a 
silica plug. BHT was eluted with CH2Cl2 and discarded. The plug was washed with 
methanol. The filtrate was concentrated using a rotary evaporator and compound 5 was 
used immediately. In a Schlenk tube fitted with a magnetic stir bar, alkyne-funtionalized 
CTA 7 (23 mg, 0.08 mmol, 1.0 equiv.), 5 (450 mg, 1.0 mmol, 13 equiv.) and 
azobisisobutyronitrile (AIBN) (4.9 mg, 0.03 mmol, 0.38 equiv.) were combined in 
acetonitrile (3 mL) and degassed by bubbling argon through the reaction mixture for 30 
minutes at 0 °C. The reaction was then heated at 75 °C for 3  hours. The resulting filtrate 
was concentrated, dissolved in minimal amount of DMF and purified by dialysis against 
methanol using a 2 kg mol-1 MWCO membrane. 1H NMR (600 MHz, CDCl3): δ 0.94 (t, 
3H, J = 7.2 Hz), 1.17-1.20 (m, 6H), 1.42-1.44 (m, 5H), 1.50-1.69 (m, 8H), 1.99-2.17 (m, 
96H), 3.37-4.15 (m, 48H), 4.55-4.67 (m, 8H), 5.06-5.14 (m, 12H), 5.40 (bs, 6H). Mn 
based on 1H NMR spectroscopy = 2970 g mol-1. SEC (DMF): Mn = 4160 g mol-1, Mw = 
5480 g mol-1, Đ = 1.32. FTIR: 1745, 1218, 1046 cm-1. 
PAcGal15 
This polymer was synthesized as described above for PAcGal6 except that the following 
quantities were used: CTA 7 (14 mg, 0.05 mmol, 1.0 equiv.), 5 (550 mg, 1.2 mmol, 25 
equiv.) and AIBN (2.7 mg, 0.02 mmol, 0.40 equiv.), acetonitrile (2.8 mL). Reaction time 
= 12 hours. Yield = 47%. 1H NMR (600 MHz, CDCl3): δ 0.87 (t, 3H, J = 7.0 Hz), 1.10-
1.65 (m, 43H), 1.91-2.09 (m, 194H), 2.39 (m, 9H), 3.60-4.08 (m, 72H), 4.49-4.57 (m, 
14H), 4.96-5.04 (m, 29H), 5.33 (bs, 15H). Yield = 47%. Mn based on 1H NMR 
spectroscopy = 7000 g mol-1. SEC (DMF): Mn = 9040 g mol-1, Mw = 11030 g mol-1, Đ = 
1.22. FTIR: 1745, 1218, 1046 cm-1. 
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PAcGal29 
This polymer was synthesized as described above for PAcGal6 except that the following 
quantities were used: CTA 7 (14 mg, 0.05 mmol, 1.0 equiv.), 5 (1.06 g, 2.38 mmol, 48 
equiv.) and AIBN (2.7 mg, 0.02 mmol, 0.4 equiv.), acetonitrile (2.65 mL). Reaction time 
= 17 hours. Yield = 47%. 1H NMR (600 MHz, CDCl3): δ 0.88 (m, 3H), 1.11-1.72 (m, 
75H), 1.92-2.11 (m, 380H), 2.99 (bs, 10H), 3.31-4.10 (m, 205H), 4.56-4.59 (m, 30H), 
5.01-5.05 (m, 58H), 5.34 (bs, 29H). Mn based on 1H NMR spectroscopy = 13260 g mol-1. 
SEC (DMF): Mn = 10900 g mol-1, Mw = 13290 g mol-1, Đ = 1.22. FTIR: 1745, 1218, 1046 
cm-1. 
Synthesis of PGal6 and general procedure for synthesis of PGaln 
PAcGal6 (170 mg, 0.057 mmol) was dissolved in anhydrous MeOH (3 mL) in a flame-
dried flask fitted with a magnetic stir bar. To the flask, 25% sodium methoxide in MeOH 
(0.34 mL) was added dropwise and then stirred at room. The reaction was stirred for 
approximately 4 hours. The pH of the reaction mixture was then adjusted to 7 using 
saturated NH4Cl and then concentrated under reduced pressure. PAcGal6 was purified by 
dialysis against pure water using a 2 kg mol-1 MWCO membrane and then was 
lyophilized to provide a fluffy white solid. Yield = 82%. 1H NMR (600 MHz, D2O): δ 
1.03-1.15 (m, 6H), 1.25-1.28 (m, 2H), 1.32-1.35 (m, 2H), 1.55-2.26 (m, 22H), 3.33-4.06 
(m, 75H), 4.41 (bs, 6H). Mn based on 1H NMR spectroscopy = 1950 g mol-1. FTIR: 3301, 
1646, 1072, 1041 cm-1. 
PGal15 
This polymer was synthesized as described above for PGal6 except that the following 
quantities were used: PAcGal15 (100 mg, 0.034 mmol), 25% sodium methoxide in MeOH 
(0.146 mL) and anhydrous MeOH (2 mL). Yield = 78%.  1H NMR (600 MHz, D2O): δ 
1.14-1.15 (m, 2H), 1.25-1.27 (m, 2H), 1.33-1.36 (m, 1H), 1.50-2.41 (m, 45H), 3.43-4.07 
(m, 151H), 4.42 (bs, 15H). Mn based on 1H NMR spectroscopy = 4450 g mol-1. FTIR: 
3301, 1646, 1072, 1041 cm-1. 
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PGal29 
This polymer was synthesized as described above for PGal6 except that the following 
quantities were used: PAcGal29 (574 mg, 0.043 mmol), 25% sodium methoxide in MeOH 
(0.356 mL) and anhydrous MeOH (10 mL). Yield = 85%.  1H NMR (600 MHz, D2O): δ 
1.15-1.17 (m, 4H), 1.25-1.27 (m, 6H), 1.48-2.23 (m, 91H), 3.42-3.97 (m, 315H), 4.42 (bs, 
29H). Mn based on 1H NMR spectroscopy = 8330 g mol-1. FTIR: 3301, 1646, 1072, 1041 
cm-1. 
Preparation of functionalized PBD-b-PEO-N3 vesicles 
For the 100% functionalized vesicles, PBD-b-PEO-N3 (50 mg) was dissolved in 1 mL of 
CH2Cl2 in a 25 mL round bottom flask. For the 10% functionalized vesicles, PBD-b-
PEO-N3 (5 mg) and PBD b-PEO (45 mg) were used. A nile red solution in CH2Cl2 was 
then added to obtain an accurate loading of 0.1 w/w% of nile red relative to the 
copolymers. The CH2Cl2 was removed under a stream of argon to produce a film of 
polymer on the flask. Deionized (DI) water (1 mL/10 mg of polymer) was then added and 
the solution was stirred for 0.5 h at 45 °C. The solution was then sonicated for 0.5 h and 
finally stirred for 24 h at 45 °C. The polymersomes were then extruded two times through 
each of 1000 nm, 400 nm, 200 nm and 100 nm polycarbonate membranes (Whatman, 
Nuclepore) at 45 °C using a pressure driven Lipex Thermobarrel Extruder (1.5 mL 
capacity, Northern Lipids). The resulting vesicles were characterized by dynamic light 
scattering (DLS) and transmission electron microscopy (TEM).  
TEM 
The vesicle suspension (prepared as described above, 10 µL of 0.1 mg mL-1) was placed 
on a Formvar®/carbon grid and was left to stand 5 min. The excess solution was then 
blotted off using a piece of filter paper. The resulting sample was consecutively imaged 
using a Phillips CM10 microscope operating at 80 kV with a 40 µm aperture. 
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General procedure for surface conjugation by click chemistry 
Vesicles were prepared as described above at a concentration of 10 mg/mL of polymer. A 
solution of copper (II) sulfate pentahydrate (CuSO4⋅5H2O), sodium ascorbate, 
bathophenanthrolinedisulfonic acid disodium salt hydrate, and PGaln was added in 
sequence such that the reaction mixture contained 1 mM CuSO4, 25 mM sodium 
ascorbate, 2.3 mM bathophenanthrolinedisulfonic acid and 4 equivalents of PGaln with 
respect to PBD-b-PEO-N3. The reaction mixture was stirred at room temperature 
overnight and then dialyzed against water overnight using a 25 kg mol-1 MWCO 
membrane. The resulting suspension was lyophilized and the product was characterized 
by FTIR spectroscopy. 
 
3.3 Results and Discussion 
 
Scheme 3.1. Synthesis of acrylamide-functionalized β-D-galactose monomer (6). 
An acrylamide-functionalized β-D-galactose monomer was synthesized as shown in 
Scheme 3.1.  A selective glycosylation of D-galactose pentaacetate (1)19 with 2-
azidoethanol (2) in the presence of BF3⋅OEt2 yielded compound 3 as only the β anomer.19 
The azide group in compound 3 was then reduced to an amine using a Lindlar-catalyzed 
hydrogenation. The resulting compound (4) was treated with acryloyl chloride in the 
presence of DIPEA and DMAP to yield compound 5 bearing acrylamide functionality. It 
was discovered that compound 5 readily polymerizes and as a result, small amounts of 
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BHT was added to the product as a radical inhibitor before solvent was evaporated from 
the product. During purification by column chromatography, BHT was also added to the 
eluent to prevent polymerization. Lastly, a deprotection of compound 5 was performed 
using sodium methoxide to yield compound 6.19 
 
 
Scheme 3.2. Synthesis of PBD-b-PEO-CTA from 2-(butylthiocarbonothioylthio)-2-
methylpropanoic acid.  
 
 
Scheme 3.3. Self-assembly of CTA functionalized vesicles in the presence of nile red and 
subsequent polymerization of monomer 6 from the surface. 
 
Following the synthesis of monomer, PBD-b-PEO was functionalized with CTA. This 
was achieved by first preparing the acid chloride derivative of 2-
(butylthiocarbonothioylthio)-2-methylpropanoic acid using thionyl chloride in order to 
produce a highly reactive acylating reagent (Scheme 3.2). The acid chloride derivative 
was then reacted with PBD-b-PEO resulting in functionalization of ~85% of the terminal 
hydroxyl groups according to 1H NMR spectroscopy.  
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Scheme 3.4. Synthesis of PEO2K-CTA and control polymerization with 6. 
Characterization of glycopolymers polymerized from vesicles is complex and 
problematic due to their assembled nature and lack of a common solvent for PBD, PEO 
and the glycopolymer (see Figure A2.3). As a result, a control study was performed using 
PEO (Mn = 2000 g mol-1) functionalized with CTA to provide a fully water-soluble 
polymer. Functionalization of PEO with 2-(butylthiocarbonothioylthio)-2-
methylpropanoic acid was performed via a DCC coupling. The resulting PEO-CTA, 6 
(100 equiv.), and the water-soluble initiator VA-044 were combined and heated at 45 °C. 
Half of the reaction mixture was removed after 10 hours and quenched by exposure to air. 
The other half of the reaction was polymerized for 24 hours and then quenched by 
exposure to air. Size exclusion chromatography (SEC) data shown in Figure 3.3 indicated 
that a 10-hour polymerization lead to glycopolymers with 8 saccaride units whereas 
polymerizing for 24 hours yielded glycopolymers with 21 saccaride units with low 
dispersities (Đ = 1.13). These results indicate only a 20% conversion after 24 hours, 
which is unusual and undesirable using this technique. Additionally, SEC data indicated a 
broad shoulder suggesting the presence of a high molecular weight impurity (Figure 3.3). 
This impurity is likely from uncontrolled polymerization of the monomer before use. 
This impurity may also help to explain the low conversion of monomer as there would be 
less monomer available to undergo controlled RAFT polymerization. Due to the low 
conversion of monomer and high molecular weight impurity present in the control study, 
an alternative strategy was taken to provide glycopolymer-coated vesicles. This 
alternative approach instead involved a more traditional strategy in which premade 
glycopolymers could be conjugated to the surface of preassembled azide-functionalized 
vesicles using alkyne-azide click chemistry. 
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Figure 3.3. SEC data of polymerizations of β-D-galactose from CTA functionalized PEO 
as a control. 
For this second approach, β-D-galactose pentaacetate possessing acrylamide functionality 
(5) was selected as the monomer to afford acetylated glycopolymers due to the tendency 
of the deprotected β-D-galactose monomer (6) to undergo uncontrolled radical 
polymerization resulting in a high molecular weight impurity. For the preparation of the 
acetylated glycopolymers using RAFT polymerization, CTA 718 possessing a terminal 
alkyne moiety was used along with AIBN as the initiator and the polymerization was 
conducted in acetonitrile at 75 °C (Scheme 3.5). During preliminary polymerizations, it 
was discovered that glycopolymer degree of polymerization plateaus at ~35 units even at 
monomer equivalents as high as 100, relative to CTA. This plateau is likely due to the 
bulky nature of the monomer. As a result, no more than 48 equivalents of monomer was 
used for further polymerizations. In order to investigate the effect of glycopolymer length 
on protein binding, 12, 25, and 48 equivalents of monomer 5 relative to CTA were used 
to provide three glycopolymers of varying lengths (Table 3.2). Evaluation of the 1H NMR 
spectra prior to purification showed that the conversion of 5 varied from 50-60%. The 
polymers were subsequently purified by dialysis against methanol using a 3500 g mol-1 
MWCO membrane.  
Time (h) DPn Mn (g/mol) Đ
10 8 4,400 1.13
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Scheme 3.5. Synthesis of PAcGaln using RAFT polymerization and subsequent 
deprotection to provide PGaln glycopolymers. 
The resulting glycopolymers were characterized by 1H NMR spectroscopy, FTIR 
spectroscopy, and SEC. The DP was determined using 1H NMR spectroscopy by 
comparing the integration of the peak at 0.94 ppm corresponding to the 3 hydrogens on 
the terminal methyl group of the CTA with that of the multiplet at 5.4 ppm corresponding 
to the anomeric proton on the galactose. This indicated that DPs of 6, 15, and 29 were 
obtained for glycopolymers PAcGal6, PAcGal15 and PAcGal29, respectively. These values 
are in agreement with the number of equivalents and the conversion observed by NMR 
spectroscopy.  From these DPs, the number average molar mass (Mn) was calculated for 
each polymer (Table 3.2). These ranged from 2970 g mol-1 for PAcGAL6 to 13290 g mol-
1 for PAcGal29. The molar masses were also measured by SEC in DMF relative to 
poly(methyl methacrylate) standards. As shown in Table 3.2, the Mns were in good 
agreement with those obtained by NMR spectroscopy and the Đ was less than 1.4 for 
each glycopolymer. The SEC traces are included in the appendix (Figures A2.14-A2.16). 
The acetylated glycopolymers were then deprotected using sodium methoxide in 
methanol. Successful deprotection was indicated by the absence of the acetate peaks at 
1.99-2.17 ppm (Figures A2.10-A12). The deprotected glycopolymers were characterized 
by 1H NMR and FTIR spectroscopy. 
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Figure 3.4. 1H NMR spectra of a) PAGal6, b) PAcGal15, c) PAcGal29, and d) protected β-
D-galactose monomer (5). 
Table 3.2. Summary of PAcGal glycopolymers synthesized for this study and their molar 
mass characteristics. 
Glycopolymer Equiv. of 
5 added 
DP of 5 
(NMR) 
% Conversion  
(NMR) 
Mn (g mol-1) 
(NMR) 
Mn (g mol-1) 
(SEC) 
Đ  
(SEC) 
PAcGal6 12 6 50 2970 4160 1.32 
PAcGal15 25 15 60 7000 9040 1.22 
PAcGal29 48 29 60 13260 10900 1.22 
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Following the synthesis and characterization of PGaln glycopolymers, vesicles with 
surface azide groups were prepared as previously reported (Scheme 3.3).21 In order to 
control the percentage of glycopolymer on the vesicle surface, vesicles of PBD-b-PEO 
and PBD-b-PEO-N3 with either 10 or 100% PBD-b-PEO-N3 were prepared by hydration 
of a thin film in the presence of the hydrophobic dye nile red. The vesicles were then 
extruded through a 100 nm pore diameter membrane to reduce their diameters. The 
resulting vesicles were characterized using DLS and TEM (Figure 3.6). This showed that 
the diameters were approximately 200 nm. The larger diameter relative to the extrusion 
pore size can likely be attributed to the flexibility of the vesicles. Ambient temperature at 
which the extrusion was performed is above the Tg of the PBD, meaning that it would 
exist in a flexible rubbery state. 
Scheme 3.6. Preparation of PBD-b-PEO vesicles with azide functionality presented on 
the surface. 
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Figure 3.5. a) DLS intensity distribution and b) TEM image of extruded PBD-b-PEO 
vesicles containing 10% PBD-b-PEO-N3 before click reaction. 
Cycloaddition reactions between the azide-functionalized vesicles and alkyne-terminated 
glycopolymers were performed over 24 hours using 1 mM CuSO4, 25 mM sodium 
ascorbate, 2.3 mM bathophenanthrolinedisulfonic acid and 4 equivalents of PGaln with 
respect to PBD-b-PEO-N3. Excess PGaln was then removed by dialysis against purified 
water. The resulting glycopolymer-coated vesicles were analyzed using 1H NMR 
spectroscopy in D2O. However, quantification of glycopolymer on the vesicle surface 
was not possible due to the extent of overlapping peaks from the glycopolymer and PEO. 
As a result, the efficacy of the click reaction between PGaln and azide was approximated 
through FTIR spectroscopy (Figure 3.6). The percent reduction of the azide peak at 2110 
cm-1 was used to quantify the coupling efficacy. However, for the click reaction between 
PGal15 and 100% azide-functionalized vesicles, a complete disappearance of the azide 
peak was observed. It should be noted that approximately 50% of the azides should be 
located in the interior of the vesicles and thus inaccessible to the glycopolymer, which is 
unlikely to diffuse through the vesicle membrane. However, a conjugation yield higher 
than 50% was obtained, which is consistent with previous studies.21,22 This may be 
explained by the dynamic nature of the vesicles, allowing polymer chains functionalized 
with azide contained in the vesicle interior to migrate to the vesicle exterior during the 
24-hour reaction period. The attachment of glycopolymer to the PBD-b-PEO-N3 vesicles 
can further be confirmed by the appearance of a broad OH stretch at 2930 cm-1. However, 
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for the click reaction between PGal15 and 10% azide-functionalized vesicles, FTIR 
spectroscopy was not a viable strategy for the quantification of coupling efficacy as no 
azide peak from the vesicles could be detected before the reaction with glycopolymer. 
This is likely due to the high molecular weight (10 kg mol-1) of PBD-b-PEO and low 
abundance of making the azide peak undetectable. This finding demonstrates that 
quantification using FTIR should be used with caution as disappearance of the azide peak 
does not infer complete conversion but rather that the azide peak is too weak to be 
detected. 
 
Figure 3.6. FTIR spectra of PBD-b-PEO-N3 vesicles and click reaction between PGal15 
and 100% azide-functionalized vesicles. 
 
3.4 Conclusions 
Synthesis of a β-D-galactose monomer with an acrylamide functionality was achieved 
over 4 steps. First, an approach involving the polymerization of the monomer from the 
vesicle surface via RAFT polymerization was explored. However, difficulties involving 
homopolymerization of the deprotected galactose monomer 6 and separation of the 
resulting high molecular weight homopolymer were encountered. Thus another approach 
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involving the conjugation of pre-synthesized glycopolymers to the vesicle surface was 
explored. Alkyne-functionalized glycopolymer with low, medium and high degree of 
polymerization and relatively low dispersities (1.22-1.32) were synthesized by RAFT 
polymerization. PBD-b-PEO was functionalized with an azide moiety followed by its 
self-assembly into vesicles to give loadings of either 10 or 100% azide on the surface. 
Glycopolymer was then conjugated to the azide-functionalized vesicles by a copper(I) 
catalyzed 3 + 2 “click” cycloaddition. FTIR spectroscopy suggested a high conjugation 
yield. However, further work will be required to better quantify this reaction, characterize 
the resulting vesicles and evaluate their capacities to bind to lectin. 
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Chapter 4  
4.1 Conclusions and Future Work 
The work described in this thesis presented the synthesis of novel polymeric systems for 
potential use in drug delivery and other biomedical applications. The development of 
functional polymeric nanocarriers that are biocompatible, biodegradable and possess 
targeting capabilities are highly desirable. Shown here is the synthesis of novel polyester 
block copolymers PEO-b-PHEL bearing pendant alkenes that can be easily functionalized 
using thiol-ene click chemistry. It has been demonstrated that the morphology of the 
parent PEO-b-PHEL copolymers can be tuned through the attachment of various small 
molecules to obtain a variety of desirable morphologies including spherical micelles, 
cylindrical micelles and vesicles. This provides a flexible platform for the synthesis of 
copolymers that vary in the composition of their core-forming blocks from a single 
polymer precursor which has not been previously described for polyesters. It was also 
shown that this strategy can be used for the attachment of an anticancer drug and 
fluorescent dye, paclitaxel and rhodamine B, respectively. PEO-b-PHEL-RHD was found 
to self-assemble into spherical compound micelles while the self-assembly of PEO-b-
PHEL-PTX34 resulted in macroscopic precipitation. Further studies will investigate the 
effect of lowering the amount of paclitaxel conjugated to PEO-b-PHEL on the self-
assembly behavior in order to obtain paclitaxel-loaded polymeric assemblies for use in 
drug delivery. In theory, once administered into the body the synthesized paclitaxel-
loaded nanocarriers would accumulate in the extracellular matrix (ECM) of the tumor 
cells as a result of the enhanced permeability and retention (EPR) effect of tumor tissue. 
The ester linkage connecting paclitaxel to the polymer backbone could then undergo 
enzymatic hydrolysis by biological enzymes rendering the original paclitaxel structure 
unaltered. However, this linkage is not very selective. Due to the increased acidity of the 
ECM of tumor cells, changing the linkage to something pH sensitive such as an acetal 
could provide a stimuli-responsive release of the drug cargo at the tumor site.1 
Also described in this thesis was the synthesis of glycopolymer-functionalized vesicles to 
afford vesicles with varying glycopolymer lengths and densities on the surface. The first 
approach presented involving polymerization of a β-D-galactose monomer (6) from the 
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surface of preassembled vesicles functionalized with CTA proved to be challenging due 
to their assembled nature and lack of a common solvent for the three blocks, leading to 
incomplete characterization. The second approach described the synthesis of well-defined 
glycopolymers possessing alkyne functionality obtained using RAFT polymerization. 
These glycopolymers were then conjugated to preassembled azide-functionalized vesicles 
using a copper(I) catalyzed 3 + 2 “click” cycloaddition. However, quantification of 
glycopolymer on the vesicle surface was problematic for similar reasons as seen with the 
previous system investigated. Due to the problems associated with characterization of the 
glycopolymer-coated vesicles using standard techniques, another approach should be 
utilized in order to more accurately quantify the amount of glycopolymer being added to 
the vesicle surface. One method by which this could be achieved is through the utilization 
of the trithiocarbonate group present in the CTA which becomes incorporated into the 
terminus of the glycopolymers. It has been demonstrated that these terminal 
functionalities are easily converted to thiols2 that can be further reacted with other 
molecules such as proteins3,4 or dyes.5 Attachment of a fluorescent dye to the terminus of 
the glycopolymers surrounding the vesicles would allow quantification using 
fluorescence spectroscopy. Rhodamine B would be a good candidate for this purpose as it 
is water-soluble, inexpensive and synthetically versatile.6 Cleavage of the terminal 
trithiocarbonate end group could be accomplished by reacting 1-hexylamine in the 
presence of tributylphosphine resulting in a thiol (Scheme 4.1).4 The resulting polymer 
could then be treated with a reactive Rhodamine B derivative to obtain fluorescently 
labelled glycopolymer, which when conjugated to the vesicles would be quantifiable by 
fluorescence spectroscopy. This fluorescent labelling combined with FTIR spectroscopy 
should provide an estimation for the amount of glycopolymer that was successfully 
attached to the vesicles. 
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Scheme 4.1. Preparation of Rhodamine-labeled polymersomes for quantification of 
glycopolymer chains. 
Once proper characterization has been achieved, the biological properties of the resulting 
glycopolymer-coated vesicles will be explored. As a first step, lectin-binding studies will 
be performed on agarose bound lectin in order to examine the effect of glycopolymer 
density and length on protein binding which has not previously been investigated. The 
findings of these binding studies will provide valuable insight into how glycopolymer 
chain length and density influence saccharide-protein binding strength in order to develop 
biomaterials with optimal binding capabilities. 
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Appendix 1 
This appendix and compounds 1-4 included within correspond to the molecules described 
in Chapter 2. 
 
Figure A1.1. 1H NMR spectrum of 2 (600 MHz, CDCl3). 
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Figure A1.2. 1H NMR spectrum of 3 (600 MHz, CDCl3). 
 
Figure A1.3. 1H NMR spectrum of 4 (600 MHz, CDCl3). 
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Figure A1.4. 1H NMR spectrum of PEO45-b-PHEL23 (600 MHz, CDCl3). 
 
Figure A1.5. 1H NMR spectrum of PEO45-b-PHEL45 (600 MHz, CDCl3). 
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Figure A1.6. 1H NMR spectrum of PEO45-b-PHEL79 (600 MHz, CDCl3). 
 
Figure A1.7. 1H NMR spectrum of PEO45-b-PHEL45-octyl (600 MHz, CDCl3). 
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Figure A1.8. 1H NMR spectrum of PEO45-b-PHEL45-TEG (600 MHz, CDCl3). 
 
Figure A1.9. 1H NMR spectrum of PEO45-b-PHEL45-acid (600 MHz, CDCl3). 
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Figure A1.10. 1H NMR spectrum of PEO45-b-PHEL45-PTX34 (600 MHz, CDCl3). 
 
Figure A1.11. 1H NMR spectrum of PEO45-b-PHEL45-RHD (600 MHz, CDCl3). 
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Figure A1.12. ATR-FTIR spectra of PEO45-b-PHEL23. 
 
Figure A1.13. ATR-FTIR spectra of PEO45-b-PHEL45. 
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Figure A1.14. ATR-FTIR spectra of PEO45-b-PHEL79. 
 
Figure A1.15. ATR-FTIR spectra of PEO45-b-PHEL45-octyl. 
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Figure A1.16. ATR-FTIR spectra of PEO45-b-PHEL45-TEG. 
 
 
 
Figure A1.17. ATR-FTIR spectra of PEO45-b-PHEL45-acid. 
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Figure A1.18. ATR-FTIR spectra of PEO45-b-PHEL45-PTX34. 
 
Figure A1.19. ATR-FTIR spectra of PEO45-b-PHEL45-RHD. 
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Figure A1.20. SEC trace for PEO45-b-PHEL23. 
 
Figure A1.21. SEC trace for PEO45-b-PHEL45. 
 
Figure A1.22. SEC trace for PEO45-b-PHEL79. 
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Figure A1.23. SEC trace for PEO45-b-PHEL45-octyl. 
 
Figure A1.24. SEC trace for PEO45-b-PHEL45-TEG. 
 
Figure A1.25. SEC trace for PEO45-b-PHEL45-PTX34. 
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Figure A1.26. SEC trace for PEO45-b-PHEL45-RHD. 
 
 
Figure A1.27. DSC curve for PEO45-b-PHEL23 (obtained from third heating cycle). 
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Figure A1.28. DSC curve for PEO45-b-PHEL45 (obtained from third heating cycle). 
 
 
Figure A1.29. DSC curve for PEO45-b-PHEL79 (obtained from third heating cycle). 
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Figure A1.30. DSC curve for PEO45-b-PHEL45-octyl (obtained from fourth heating 
cycle). 
 
 
Figure A1.31. DSC curve for PEO45-b-PHEL45-TEG (obtained from fourth heating 
cycle). 
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Figure A1.32. DSC curve for PEO45-b-PHEL45-acid (obtained from third heating cycle). 
 
 
Figure A1.33. DSC curve for PEO45-b-PHEL45-PTX34 (obtained from third heating 
cycle). 
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Figure A1.34. DSC curve for PEO45-b-PHEL45-RHD (obtained from third heating cycle). 
 
Table A1.1. Summary of the thermal stabilities of PEO-b-PHELs measured by TGA. 
T98% = maximum temperature at which 98% of mass is still present; To = onset 
degradation temperature. 
Polymer T98% (°C) To (°C) 
PEO45-b-PHEL23 223 262 
PEO45-b-PHEL45 156 270 
PEO45-b-PHEL79 243 262 
PEO45-b-PHEL45-octyl 148 273 
PEO45-b-PHEL45-TEG 142 258 
PEO45-b-PHEL45-acid 232 246 
PEO45-b-PHEL45-PTX34 114 221 
PEO45-b-PHEL45-RHD 214 247 
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Figure A1.35. TGA curve for PEO45-b-PHEL23. 
 
 
Figure A1.36. TGA curve for PEO45-b-PHEL45. 
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Figure A1.37. TGA curve for PEO45-b-PHEL79. 
 
 
Figure A1.38. TGA curve for PEO45-b-PHEL45-octyl. 
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Figure A1.39. TGA curve for PEO45-b-PHEL45-TEG. 
 
 
Figure A1.40. TGA curve for PEO45-b-PHEL45-acid. 
 
142.07°C
98.00%
258.19°C
289.16°C
­5
0
5
10
15
20
D
er
iv
. W
ei
gh
t (
%
/m
in
)
­20
0
20
40
60
80
100
W
ei
gh
t (
%
)
0 100 200 300 400 500 600
Temperature (°C)
Sample: JTM­238­2
Size:  5.3370 mg
Method: Ramp
Comment: RT to 500
DSC­TGA File: F:\TGA\JTm­238­2.002Operator: JAP
Run Date: 21­May­2015 10:59
Instrument: SDT Q600 V20.7 Build 17
Universal V4.5A TA Instruments
246.18°C
268.61°C
49.87%
231.79°C
98.01%
0
20
40
60
80
100
120
W
ei
gh
t (
%
)
0 100 200 300 400 500 600
Temperature (°C)
Sample: BR150
Size:  2.7570 mg
Method: Ramp to 1000
TGA File: Z:...\TGA DSC\Brooke tga\BR150­4.001Operator: bo
Run Date: 24­May­2016 12:41
Instrument: TGA Q50 V20.13 Build 39
Universal V4.5A TA Instruments
  
99 
 
Figure A1.41. TGA curve for PEO45-b-PHEL45-PTX34. 
 
 
Figure A1.42. TGA curve for PEO45-b-PHEL45-RHD. 
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Appendix 2 
This appendix and compounds 1-7 included within correspond to the molecules described 
in Chapter 3.  
 
Figure A2.1. 1H NMR of acrylamide functionalized β-D-galactose pentacetate monomer 
(5) immediately before polymerization (600 MHz, CDCl3).  
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Figure A2.2. 1H NMR of purified β-D-galactose monomer possessing acrylamide 
functionality (6) (600 MHz, D2O). 
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Figure A2.3. 1H NMR spectra of β-D-galactose monomer, CTA-functionalized PBD-b-
PEO vesicles, polymerization at t = 18 h, and t = 48 h (bottom to top).  
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Figure A2.4. 1H NMR of prop-2-ynyl-2-(butylthiocarbonothiolthio)-2-methylpropanoate 
alkyne RAFT CTA (600 MHz, CDCl3). 
  
Figure A2.5. 1H NMR of 2-azidoacetic acid (600 MHz, CDCl3). 
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Figure A2.6. 1H NMR of PBD-b-PEO-N3 (600 MHz, CDCl3). 
  
Figure A2.7. 1H NMR of PAcGal6 (600 MHz, CDCl3). 
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Figure A2.8. 1H NMR of PAcGal15 (600 MHz, CDCl3). 
 
Figure A2.9. 1H NMR of PAcGal29 (600 MHz, CDCl3).  
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Figure A2.10. 1H NMR of PGal6 (600 MHz, D2O).  
Figure A2.11. 1H NMR of PGal15 (600 MHz, D2O).  
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Figure A2.12. 1H NMR of PGal29 (600 MHz, D2O).  
 
Figure A2.13. 1H NMR of click reaction between PGal15 and 10% azide-functionalized 
vesicles (600 MHz, D2O). 
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Figure A2.14. SEC trace for PAcGal6. 
 
Figure A2.15. SEC trace for PAcGal15. 
 
Figure A2.16. SEC trace for PAcGal29.
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